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Abstract Study 1 
Cardiovascular safety of DPP-4 inhibition in participants with Type 2 
Diabetes Mellitus: Endothelial Progenitor Cells as an early marker of 
long-term cardiovascular risk 
Endothelial Progenitor Cells (EPCs) play a central role in cardiovascular 
repair and increasing EPC number is a strong determinant of future 
cardiovascular risk(1). Interventions, which modify cardiovascular risk, 
have early effects on EPC number and function (2). Establishing 
cardiovascular safety of any new anti-diabetic agent typically requires 
long-term post-marketing trials. DPP-4 inhibitors are a new class of 
glucose-lowering medication(3). We aimed to evaluate the long-term 
cardiovascular safety of Saxagliptin (SAX, a DPP-4 inhibitor) versus 
Gliclazide Modified Release (GLC) using EPC number and function as 
surrogate markers of cardiovascular risk. 18 participants with T2DM on 
Metformin monotherapy were randomized to SAX (n=7) or GLC (n=11).  
EPC number and adhesion capacity were measured, using methods as 
previously described (4), at baseline and at 6 months after treatment. 
There was no difference in the median EPC number of 33 (19 – 44) vs. 
25 (22 – 46) cells per high power field (HPF), p=0.9) or adhesion capacity 
of 0.22 (0.17 – 0.86) vs. 0.27 (0.1 – 0.67 fluorescence units, p=0.75) at 
baseline between SAX and GLC groups respectively. Compared to 
baseline there was no change in median EPC number [SAX: 35 (28-38) 
vs 33 (19-44) cells/HPF, p=0.9 and GLC: 39 (28-46) vs 25 (22-46) cells/ 
HPF, p=0.24] or adhesion capacity [SAX: 0.3 (0.17 – 0.65) vs 0.22(0.17 – 
0.86), p=1.0, GLC: 0.32 (0.14 – 0.84) vs 0.27 (0.1 – 0.67) fluorescence 
units, p=0.88] after 6 months treatment in either group. In summary, we 
found no difference in EPC number or function in participants treated with 
SAX versus GLC for 6 months. These results may suggest a similar 
cardiovascular safety profile of SAX to GLC, a well-established treatment 
for T2DM. 
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Abstract Study 2 
The Effect of Taurine on Endothelial Dysfunction In Type 2 Diabetes 
Mellitus: A Pilot Study 
There is a two- to three-fold increase in cardiovascular (CVD) mortality in 
T2DM patients compared to aged-matched non-diabetic subjects(5). 
Endothelial dysfunction characterized by arterial stiffness predicts this 
CVD risk(6). Endothelial Progenitor Cells (EPCs) are bone marrow 
derived cells responsible for cardiovascular repair, act as a surrogate 
biological marker for vascular dysfunction, and predict cumulative future 
cardiovascular risk(7). Taurine is a sulfur-containing amino acid, 
synthesized in the body in limited amounts, and is present mainly in 
seafood(8, 9) which has been shown to have a beneficial effect in 
hypertension(10, 11), hypercholesterolaemia(12, 13), and endothelial 
function (14, 15). Taurine supplementation for 2 weeks improves arterial 
stiffness in patients with T1DM(16). We carried out a pilot study 
examining the effects of taurine on 11 T2DM patients in a randomized, 
double blind, cross-over placebo design. We evaluated any changes to 
EPC numbers and function. We also compared the degree of arterial 
stiffness using PWV. There was a trend towards an improvement in the 
number of EPC/hpf following taurine (40 ± 7 cells) and placebo (37 ± 10 
cells) when compared to baseline (32 ± 8 cells, p=0.08). Similarly, there 
was a trend towards improvement in DBP following taurine (78.6 ± 7.4 
mmHg) and placebo (79.3 ± 7.5 mmHg) when compared to baseline 
(86.3 ± 10.2mmHg, p=0.08). There were no differences in the EPC 
adhesion capacity between baseline (n=10, 0.66 ± 0.4 fluorescence unit), 
taurine (10, 0.97 ± 0.8 fluorescence unit) and placebo (11, 0.94 ± 0.5, 
p=0.43 fluorescence unit) group. There were also no differences in the 
measurements of PWV baseline [8.7 (8.0-8.4) m/s], taurine [9.1 (8.3-9.6) 
m/s] and placebo [8.9 (8.8-9.1) m/s, p=1.0]. These results may be 
interpreted as an absence of benefit of Taurine in modulating known 
markers of endothelial dysfunction in T2DM. The downward trend in DBP 
and an upward trend in the numbers of EPC seen in this pilot study, 
however, will require further evaluation in a larger cohort.  
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1 Introduction 
1.1 Endothelial Progenitor Cells 
1.1.1 Discovery of Endothelial Progenitor Cells (EPCs) 
Endothelial Progenitor Cells (EPCs) are circulating bone marrow derived 
cells capable of postnatal vasculogenesis and vascular homeostasis (17). 
The EPC was first described by Asahara et al who demonstrated that 
circulating CD34+ cells are able to differentiate into endothelial-like cells 
ex-vivo(18).  
These haematopoietic CD34+ mononuclear cells (MBCD34+) were isolated 
from peripheral blood using magnetic beads, and seeded on fibronectin 
plates. Spindle shaped cells developed after 3 days incubation and the 
numbers of these attached cells increased with time. These attached 
cells (ATCD34+) proceeded to develop cellular networks and tube-like 
structures.  
These ATCD34+ cells were also shown to express endothelial constitutive 
nitric oxide synthase (ecNOS), Fetal Liver Kinase 1/Kinase insert Domain 
Receptor (Flk-1/KDR), TIE2 and E-Selectin which are markers of 
endothelial cell phenotype.  
To prove that these cells are involved in vessel regeneration, Asahara 
used a mouse and rabbit model of hind-limb ischaemia. Infused MBCD34+ 
cells were shown to migrate to foci of angiogenesis, proliferate, integrate 
into the capillary vessel wall, and contribute to neoangiogenesis in the 
ischaemic hind limb of the mouse and rabbit.  
Similar to Asahara’s work, Shi et al(19) demonstrated that a subset of 
CD34+ haematopoietic stem cells were able to differentiate into 
endothelial cell lineages. These cells were also expressing endothelial 
proteins such as von Willebrand factor (vWF) and were able to 
incorporate Dil-labeled LDL (Dil-LDL). In an in-vivo model, Shi et al 
transplanted genetically tagged bone marrow cells from a donor canine. A 
Dacron graft, impermeable to capillary ingrowth from the surrounding 
perigraft tissue, was implanted in the descending thoracic aorta of the 
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recipient animal. Cells with endothelial morphology were identified on the 
graft and only donor alleles were detected in DNA of these cells.  
These studies, taken together strongly suggest that a subset of CD34+ 
cells from the bone marrow can be mobilized into peripheral circulation 
and colonize endothelial surfaces. The studies challenge the original 
understanding of postnatal vasculogenesis that postnatal angiogenesis 
only occurred through proliferation, migration and remodeling of pre-
existing endothelial cells (20-22).  
1.1.2 Multiple Origin of EPC 
There are two main methods to isolate EPC. Firstly, by identifying cell 
surface progenitor cell markers such as CD34, CD 133 and endothelial 
marker VEGFR2. Secondly, by using differential cell cultures technique, 
together with growth medium on different types of adhesion surface(23, 
24) 
CD34 expressivity however, is not exclusively seen on haematopoietic 
stem cells, but also on mature endothelial cells(25)(Figure 1-1). The more 
immature haematopoietic stem cell with marker CD133 could also 
differentiate to endothelial cells in vitro(26). Using vascular endothelial 
growth factor (VEGF), which is a major inducer of vasculogenesis, stem 
cell growth factor (SCGF), granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and erythropoietin (EPO) in culture media, these 
AC133+ cells were able to differentiate into endothelial-like cells (EC) in-
vitro. The adherent EC displayed endothelial characteristics including 
expression of CD34, CD31, vascular endothelial cadherin (VE-Cadherin), 
KDR, Tie-2, Ulex eurapeus-agglutinin-1 and vWF respectively, and the 
presence of Weibel-Palade bodies(26).  
Monocytic cells, specifically the CD14+/CD34- cells may also differentiate 
into endothelial-like cells. Under angiogenic stimulation with VEGF, basic 
 18 
 
Figure 1-1 Origin and differentiation of Endothelial Progenitor Cells. 
Scheme depicts the potential origin and differentiation of EPC from 
haematopoetic stem cells and non-haematopoetic cells. (Adapted from 
Urbich et al. Circ. Res. 2004; 95; 343-353) 
fibroblast growth factors (bFGF) and insulin like growth factors (IGF-1), 
these cells were induced to express endothelial markers (vWF, VE-
cadherin and ec-NOS) and displayed similar morphology to the original 
description by Asahara et al. In the same study, CD34+ cells, under 
similar culture medium, demonstrated similar cell morphology, albeit with 
a smaller percentage compared to CD34- cells(27). The exact origin of 
monocyte-derived EPC remained to be elucidated as fresh monocyte also 
displayed typical endothelial cells characteristics (LDL-uptake, Lectin 
binding, expression of CD31, CD 105 and CD 144) making them 
indistinguishable to monocyte-derived EPC(28). Mice study however, did 
demonstrate equal improvement in neovascularization of hind-limb 
ischaemia from EPC derived from clonal expansion of either monocytic 
CD14+ or non-monocytic CD14- (29).  
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To further clarify the antigenic profile of EPC, a proteomic method was 
used to identify microparticles (MP) on EPC. As MPs retain membrane 
antigen specific from the parent cells, this made them ideal candidate to 
clarify the cellular progeny of EPC culture. Prokopi et al demonstrated 
that in a conventional EPC isolation, MPs originating from platelets were 
taken up by the mononuclear cells population during culture. This 
contributes to the currently known “endothelial” characteristics (CD31, 
vWF, and lectin-binding). This novel finding challenges the previous 
preclinical and clinical studies describing EPC cellular progeny especially 
when unselected bone marrow mononuclear cells were used(30).  
1.1.3 EPC Culture 
Cell culture methods to isolate EPC have evolved significantly since the 
original description by Asahara et al(1, 7, 31-33).  The main differences 
include culture duration, types of adhesion matrix molecule and utilizing a 
pre-plating procedure(24). 
To isolate mononuclear cells (MNCs) from peripheral bloods, a Ficoll 
density gradient centrifugation is used, and these isolated MNCs, are 
cultured on matrix molecules such as fibronectin(2, 34). Adherence to 
fibronectin, with dual positivity staining to acetylated low-density 
lipoprotein (acLDL) and Ulex Lectin are typical characteristics of EPCs 
identified in-vitro by most groups(2, 4, 7, 35, 36). The short duration 
protocol such as used in our study, yielded cells with 
myeloid/haematopoietic characteristics. The ‘early EPCs’ (after 4 days 
cultured on fibronectin surface) are spindle shaped and express CD45, 
and typical myeloid markers CD14 and CD11b(24, 32).  
In order to remove potential monocytes and macrophages, Hill et al pre-
plated MNC and selected only non-adherent cells for cultures to form 
cluster of cells with spindle shapes sprouting at the periphery termed 
colony forming unit endothelial cells (CFU-EC)(7). Similar to ‘early EPCs, 
CFU-EC also expressed similar markers of myeloid and haematopoietic 
cells (24). 
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Long-term culture of ‘early EPC’ yielded more mature endothelial cell 
phenotype, often referred to as ‘late’ or ‘outgrowing’ EPC(24). Late EPC, 
in contrast, have a cobblestone shape; appear after 2 to 3 weeks of 
culture with exponential growth at 4 to 8 weeks, and the majority are 
derived from a CD14- subpopulation(32). In a more differentiated state, 
these EPC will increase the expression of endothelial markers such as 
KDR, VE-cadherin, eNOS, caveolin-1, vWF, and CD62E(2, 37). KDR is 
generally a marker that signifies progenitor cell commitment to 
differentiate into endothelial cells, being expressed at more immature 
stage than CD31 and vWF(38). Late EPC are considered more capable 
of in-vitro tube formation compared to early EPC(29, 32). 
Culturing on collagen however, for more than 14 days formed ‘endothelial 
colony forming cells’ (ECFC)(24, 33). These cells do not have the 
haematopoietic and myeloid markers, appeared to be clonally unrelated 
to CFU-ECs and are capable of forming vascular networks(24). Although 
ECFCs are considered to be the ‘true’ EPC, the exact origin of these cells 
remains to be elucidated as they lack the progenitor markers and are 
indistinguishable from the mature endothelial cells(24).  
Some authors believe that acLDL uptake and lectin binding are no longer 
sufficient to characterize EPC and that a prolonged culture for 2 weeks 
without pre-plating is a valuable alternative compared to other 
methods(34). Many authors feel that a wider expression of endothelial 
markers (CD31, KDR, vWF and eNOS) together with typical endothelial 
cell morphology would define a minimum criterion for EPC identification; 
and that additional criteria should include identification of additional 
markers (CD45, CD34, CD133, CD 117) and further assay demonstrating 
ability of cells to incorporate into endothelium. 
Our group isolates EPCs from peripheral blood MNC and culture on 
fibronectin plates for 7 days(4, 39). We discard the non-adherent cells 
and change endothelium media on Day 4. We confirm adherent cells as 
EPCs based on the uptake of acLDL and Lectin on Day 7 adherent cells. 
We also have performed Western blot analysis and laser scanning 
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cytometry to confirm the co-expression of haematopoetic and endothelial 
stem cell markers CD34 and VEGF on the adherent cells at day 7(4). 
Based on our culture technique and the morphology of cells during 
culture, it is likely that our EPC also originated from the myeloid 
precursors(24, 27). Our methods are well established (4, 34, 39) and it 
has been used by Choi et al, linking EPCs to coronary artery disease risk 
in patients with chronic renal failure compared to healthy volunteers(40).  
1.1.3.1 Summary 
Under correct growth factor stimulation, bone marrow derived pluripotent 
cells such as haematopoetic and myeloid stem cells are able to 
differentiate into EPC. Depending on the duration of culture, MNC will 
develop into ‘early’ and ‘late’ EPC with differing characteristics. There are 
some agreements regarding the minimum criteria for identification of 
EPC; however, in order to improve the specificity of EPC identification, 
there are still areas that will require further studies. These include further 
development in in-vitro colony assays, in-vivo tracing of endothelial 
lineage, further epigenetic studies to understand transfer of material, 
intercellular communications and haemato-endothelial transition 
studies(24).  
Both flow cytometry and culture methods continue to evolve and these 
techniques are still used in various studies involving EPCs, particularly in 
the area of cardiovascular disease (CVD)(40), ischaemic stroke(35), 
pharmacology(41), diabetes and vascular(42) diseases.  
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1.1.4 Endothelial Progenitor Cells and Angiogenesis 
Endothelial Progenitor Cells contribute to angiogenesis through 
improvement in neovascularization by influencing endothelial 
regeneration (25).  
In injured or denuded arteries, EPCs have been shown to home to the 
injured site (43), induce rapid regeneration of the endothelial monolayer 
and further prevent restenosis by synthesizing anti-proliferative mediators 
such as nitric oxide (44, 45). 
In tissue ischaemia, mediated by activation of hypoxia-sensing systems, 
such as hypoxia inducible factor (HIF)-1α, there is up-regulation of VEGF 
and stromal cell-derived factor-1 α (SDF-1α) by the injured tissue(46, 47). 
These substances activate the matrix metalloproteinase-9 (MMP-9)-
dependent pathway resulting in release of progenitor cells from the bone 
marrow (48-51).  
Mobilization of bone marrow derived EPCs is the first step following 
tissue ischaemia (25)(Figure 1-2). Other potent factors helping this 
process include granulocyte-colony stimulating factor (G-CSF), GM-
CSF(51), and EPO(52, 53).   
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Figure 1-2 Mechanism of EPC homing and differentiation. Recruitment 
and incorporation of EPCs into ischemic tissue requires a coordinated 
multistep process including mobilization, chemoattraction, adhesion, 
transmigration, migration, tissue invasion, and in situ differentiation. 
(Adapted from Urbich et al. Circ. Res. 2004; 95; 343-353) 
 
The intensity of the ischaemia or injury determines the EPC incorporation 
rate. This fact was demonstrated by various studies, which illustrated 
large differences in the percentage of endothelial markers expressed (48, 
54-60) on new-formed vessels depending on the severity of the 
ischaemia. Some studies demonstrated a low incorporation rate (29, 61), 
which suggest that neovascularization does not depend solely on EPC 
incorporation, but also depends on the EPC’s paracrine release of pro-
angiogenic growth factors such as VEGF, Hepatocyte Growth Factor 
(HGF), and G-CSF (62). These growth factors may influence proliferation, 
migration and survival of mature endothelial cells(21). 
 24 
Therapeutically, HMG-CoA reductase inhibitors (statins) have been 
shown to increase the proliferation and mobilization of EPC, and to 
prevent EPC senescence and apoptosis through phosphatidylinositol 3-
kinase (PI3K/Akt pathway)(41, 59, 63, 64). Interestingly, this similar 
pathway is augmented by VEGF, EPO, estrogen and exercise suggesting 
potential sharing of a common pathway to induce EPC mobilization(25).  
Once EPC are mobilized, they adhere to sites of injury or ischaemia. 
EPCs depend on integrin protein to adhere to ischaemic endothelial cells 
and extracellular matrix protein(25). In a study using volunteers EPC, 
fibronectin receptor (composed of α5β1 integrin subunits) and αv and β5 
integrin subunits were upregulated in response to a common lipid-
lowering agent, statin. By blocking these receptors with cyclic RGD 
peptides in an animal model with carotid artery denudation, the 
incorporation of EPCs into the injured artery were significantly reduced, 
proving the functional relevance of these integrin to EPC adhesions(44). 
SDF-1α, which binds to a 7-transmembrane-spanning G protein-coupled 
chemokine receptor-4 (CXCR4), have been shown to play an important 
role in regulation of cellular function of EPCs such as mobilization from 
bone marrow, migration, proliferation, and survival (65-67). EPC 
migration is mediated by E- and P-selectins. Other molecules such as 
intracellular adhesion molecule-1/leukocyte function-associated antigen-
1/vascular cell adhesion molecule-1/very late antigen (VLA)-4 ligand pairs 
and junctional adhesion molecules strengthen the adhesions with β2 
integrins mediates the transmigration of EPC thereafter.(68)  
Little was known with regards to the downstream signal transduction 
pathway used by EPC for migration but over the last number of years, 
studies have identified the PI3K/Akt and MAPK/ERK pathways as 
potential signal transduction pathways for this purpose(41, 69-72). 
Indeed, many other cell types have been shown to require both pathways 
in facilitating migration capacity(69, 72-74). Wang et al(72) demonstrated 
that the PI3K/Akt and not the MAPK/ERK pathway was required for SDF-
1α –mediated migration of haematopoetic progenitor cells and primary 
 25 
marrow CD34+. Floridi et al and Sotsios et al however, demonstrated that 
both pathway were involved(69, 71). By using PI3K inhibitors (LY294002 
and wortmannin) and MEK inhibitor (PD98059), Zheng et al(75) indicates 
that PI3K/Akt  and not MAPK/ERK activation is involved in the SDF-
1α/CXCR4-mediated EPC migration. 
In an early animal model, Asahara et al, showed an increased EPC 
population and differentiation by nearly 5 and 4-fold respectively following 
hind-limb ischaemia(18). To investigate EPC kinetics during tissue 
ischaemia, mice with induced hind-limb ischaemia and sham-operated 
controls were used. These mice were subjected to cornea micro-pocket 
surgery. There was 1.3-fold increase in neovascularization of the cornea 
in the mouse with hind-limb ischaemia compared to mouse with non-
ischaemic sham-operated control(51). Another study used culture-
expanded EPC from human donors, which were successfully 
transplanted in an athymic mouse model with hind-limb ischaemia. The 
transplanted EPC promoted neovascularization of ischaemic tissue and 
reduced limb necrosis and autoamputation by 50%(31).  
1.1.5 EPC and Cardiovascular Disease (CVD): Clinical Studies 
The capabilities of EPC to home to sites of neovascularization and 
differentiate into endothelial cells contribute greatly to the modern 
understanding of vasculogenesis. The role of EPC in improving 
ischaemic-induced damage led to studies of EPC in influencing 
cardiovascular risk.  
In 2001, Vasa et al looked at the relationship between atherosclerotic risk 
factors and the number and functional activity of EPCs(1). Compared to 
age-matched volunteers, participants (n=45) with angiographically 
documented coronary artery disease (CAD) had 40% lower EPC level. 
There was a negative correlation between the number of risk factors and 
EPC level. Smoking was an independent predictor of reduced EPC levels 
while no association was seen with age or low-density lipoprotein (LDL) 
cholesterol. Similarly, the migratory capacity of EPC was significantly 
impaired in CAD group with negative correlation seen with the total 
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numbers of risk factors for CAD. In multivariate analysis, hypertension 
was shown to be a significant risk factor for reduction in EPC migration. In 
summary, participants with CAD had lowered EPC levels and impairment 
of functional capacity, which correlated with numbers of risk factors for 
CAD such as smoking and hypertension.  
What about in subjects without CAD who may or may not have risk 
factors for cardiovascular disease? Would similar risk factors affect EPC 
number and function prior to the development of CAD?  
To answer this, Hill et al(7) examined 45 subjects without CAD. All were 
male, with and without risk factors for cardiovascular disease. Their risk 
factor burden was calculated using the Framingham risk score, which has 
been proven to predict the risk of CAD in disease-free subjects(76).  
In this study, flow mediated brachial artery reactivity (FMBRA) also known 
as flow-mediated dilatation (FMD) was used to evaluate endothelial 
function. Endothelium-dependent vasodilatation was assessed by 
measuring the maximal increase in the diameter of brachial artery during 
reactive hyperaemia evoked by the release of cuff inflated to 255mmHg 
for 5 minutes on the upper arm, proximal to the measurement site. This is 
a well-recognized technique in the evaluation of endothelial function(77) 
and was used as a surrogate measurement of ongoing function of EPCs 
based on the risk burden.  
In subjects without CAD, adjusted for age, hypercholesterolaemia was 
significantly associated with lower EPC colony forming unit (EPC CFU). 
Framingham score was negatively correlated; while FMBRA was 
positively correlated with EPC counts. At the highest reactivity of FMBRA, 
there was 3-fold increase in the number of EPCs. In the multivariate 
analysis, FMBRA was an independent predictor of EPC counts.  
Interestingly, subjects with high and low EPC counts had preserved 
FMBRA or depressed FMBRA irrespective of the Framingham score. In 
multivariate analysis of FMBRA, when both Framingham score and 
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number of EPC inserted, EPC count was significant predictor over and 
above the effects of Framingham score.  
1.1.5.1 Summary 
Both studies(1, 7) demonstrated that EPCs from high-risk subjects were 
fewer and become senescent more rapidly compared to low-risk subjects. 
Although cause and effect were not established, the findings by Hill et al 
and Vasa et all suggest that there may be a link between prolonged 
exposure of cardiovascular risk factors, EPC physiology, endothelial 
function and coronary artery disease. Levels of EPC may act as a 
surrogate biological marker for vascular function and cumulative 
cardiovascular risk. Similarly, endothelial injury in the absence of 
sufficient circulating EPC may affect the progression of CVD(7).  
The nature of both studies was not adequate to establish cause and 
effect. In order to establish the relationship between EPC, FMBRA and 
prediction of CVD, studies where EPCs are experimentally manipulated 
and the biological and therapeutic results analyzed, were needed  
Schmidt-Lucke et al (78) were the first to demonstrate that a reduced 
level of EPC independently predicts future cardiovascular (CV) events in 
a prospective study. Subjects included participants with stable CAD 
(n=44), unstable CAD (n=33), acute coronary syndrome (ACS, n=43) and 
healthy control (n=43); with median follow up of 10 ± 12.1 (range 1-48) 
months. EPC were measured at inclusion. Subjects with CV events had 
lower EPC compared to subjects without CV events. Crude hazard ratio 
for CV events was 6.3 and after adjustment for disease activity and risk 
factor load for CAD, reduced EPC accounted for nearly 4-fold increased 
risk of suffering CV events during follow up. Thus, the number of 
circulating EPCs independently predicts atherosclerotic disease 
progression(78). Fadini et al quantified the level of CD34+ EPC in 214 
subjects with different level of CV risk.  There were negative correlations 
between the level of CD34+ cells with CV risks with a synergistic effect 
from each component of metabolic syndrome(38). Both studies support 
the role of EPC as a surrogate marker for CV risks.   
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1.1.6 Factors affecting EPCs 
Several studies have examined factors potentially modulating the number 
of EPCs. Exhaustion of EPC pool in the bone marrow, reduced 
mobilization, reduced survival, and/or differentiations have been 
suggested as possible mechanisms for a reduction in circulating EPC 
number.  
A study by Aicher et al used a mice model deficient in endothelial nitric 
oxide synthase (eNOS) and demonstrated that deficiency in eNOS 
reduced mobilization of EPCs due to reduction in vascular endothelial 
growth factor (VEGF) production(61).   
Hill et al performed cell senescence analysis in a subset of participants 
with CVD risk factors. By using β-galactosidase as a marker of cell 
senescence, they demonstrated that subjects with high risk for CVD had 
higher percentages of EPCs with a senescence phenotype compared to 
low risk subjects(7). Presence of diabetes, obesity, hypertension, 
hyperlipidaemia, previous CVD and age above 50 years old are other 
factors associated with lower level of EPC as determined by the CD34+ 
level(38). There is an inverse correlation between the levels of EPCs and 
the numbers of cigarettes smoked. Smoking cessation increased EPC 
numbers while smoking resumption decreased EPC numbers towards the 
level pre-cessation(79).   
Sata et al examined the capabilities of the hematopoietic stem cells to 
differentiate to endothelial cells. Differentiations of these bone marrow 
CD34+ cells to EPCs are dependent on the endothelial growth factors 
(e.g. VEGF)(80). This VEGF induced differentiation is further inhibited by 
oxidized LDL as demonstrated by Imanishi et al(81). When isolated 
human mononuclear cells (MNC) are incubated with VEGF and oxidized 
LDL, oxidized LDL affected the differentiation to EPC in a dose 
dependent manner through deactivation of Akt pathway. More 
importantly, this inhibitory effect induced by oxidized LDL was prevented 
by pretreatment with atorvastatin(81). Certainly, this and other studies 
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(41, 44, 59, 63, 64) provided the background for further work in the role of 
statin in improving EPC numbers and functions.  
1.1.7 Effects of Statin on EPC 
Higashi et al looked at the effect of Pravastatin on flow-mediated 
dilatation (FMD), circulating EPCs and EPC migration in subjects with low 
level of high-density lipoprotein (HDL) and no CV risk factors versus 
placebo control subjects. FMD improved after 4 weeks in treated group 
compared to placebo group. Changes in HDL, numbers and migration of 
EPC were independent predictors of augmentation of FMD with 
Pravastatin(82). 
The effect of statins on EPC was also examined in participants with 
established CAD. Participants who started atorvastatin or had an 
increase in atorvastatin dose for 4 weeks had a reduction of endothelial 
cell (EC) apoptosis by 50% with a doubling of EPC numbers compared to 
participants who were given ezetimibe in addition to stable dose of 
atorvastatin therapy(83).  
One study examined the effect of statins on EPC in participants with 
T2DM. A high risk CVD group of participants (n=26) including 19 T2DM 
participants were randomized to either Pitavastatin or Atorvastatin for 12 
weeks. Both statins reduced plasma lipid levels while higher EPC levels 
were observed in the Pitavastatin group, suggesting possible differential 
effects of different statins on EPC(84).  
More recently, a systematic review of randomized trials of statin therapy 
and EPC revealed varying percentage increases in EPC numbers with a 
median increase of 70.2%. Some of the main weaknesses in the studies 
reviewed included significant heterogeneity in patient population, statin 
type and the definition of EPC used(85). Nevertheless, there is no doubt 
that statin has significant benefit on EPC numbers and function and this 
fact contributes to our understanding of vascular remodeling and 
physiology.  
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1.1.8 Effect of Multifactorial Treatment on EPC 
Reinhard et al evaluated the effect of a multifactorial treatment strategy 
on EPC numbers in subjects with T2DM (n=28). EPC culture was 
performed at baseline and at 30 and 90 days. Patients were started on 
multifactorial treatments covering aspects of glycaemic control, lipid and 
blood pressure lowering, antithrombotic therapy and lifestyle modification. 
Metformin, statin, aspirin and Angiotensin Receptor Blocker (ARB) were 
pharmacological agents used. EPC numbers were analyzed based on 
mono-, dual-, triple- or quadruple therapy used.  There was a non-
significant increase of EPC numbers by 15% after 30 days and a 
significant increase of 35% by 90 days of multifactorial treatment 
compared to baseline. EPC count was reduced by 32% in medically 
untreated patient (n=2), and increase by 63% in patients with quadruple 
therapy(86).  
Treatment of hypertension with ARB (olmesartan and irbesartan) for 12 
weeks has been shown to increase EPC numbers in T2DM patients 
independent of blood pressure reduction to the same magnitude as 
statins(87). Additionally, in normal healthy volunteers, treatment with low 
dose aspirin (equivalent of 75mg in-vivo) has an anti-senescence, pro-
migratory and pro-adhesive effect on EPCs(88).  
Anti-diabetic medications have been shown to have positive effects on 
EPC and this will be discussed in detail in the diabetes section.  
1.1.9 Summary 
EPC are bone marrow derived cells that challenge the original 
understanding of postnatal angiogenesis. EPC has multiple origins, and 
may be identified by the presence of specific cell markers CD34, CD133, 
and KDR, together with dual staining with acLDL and Ulex lectin. EPC 
improves neovascularization, thus contributes to angiogenesis and the 
number of circulating EPCs independently predicts atherosclerotic 
disease progression. Diabetes, obesity, hypertension, hyperlipidaemia, 
and smoking are among factors identified affecting EPC differentiation, 
and mobilization.  Multidrug treatment, statin and antidiabetic treatment 
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especially Sitagliptin have been shown to improve EPC numbers and 
function.  
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1.2 Type 2 Diabetes (T2DM) 
1.2.1 Definition, Epidemiology and Diagnosis of T2DM 
Diabetes mellitus is a metabolic disorder characterized by chronic 
hyperglycaemia with disturbance of carbohydrate, fat, and protein 
metabolism resulting from defect in insulin secretion, insulin action or 
both (89).  
T2DM is characterized by a progressive insulin secretory defect on a 
background of insulin resistance. It is a complex chronic illness requiring 
continuous medical care with multifactorial risk reduction strategies 
beyond glycaemic control (90). 
The World Health Organization (WHO) reports that the age-standardized 
adult diabetes prevalence was 9.8% in men and 9.2% in women in 2008, 
up from 8.3% and 7.5% in 1980. This represents an increase from 153 
million in 1980 to 347 million in 2008(91).  
In 2005, it was estimated that the prevalence of adult diabetes (Type 1 
and Type 2) in Republic of Ireland was 4.7%, which equates to 141,063 
adults(92). In 2010, data from Institute of Public Health of Ireland 
estimated that more than 185,000 (8.9%) adults age more than 45 years 
old have diabetes. By 2020, this number is predicted to rise by 30% to 
more than 175,000 (9.1%)(93).  
1.2.2 T2DM and Cardiovascular Disease (CVD) 
Today, macrovascular complications (CVD including stroke) are the most 
common cause of death in patients with diabetes(90).  
Epidemiological and pathological data 1.5 decades ago firmly established 
diabetes as an independent risk factor for CVD in both male and female 
patients(94-96). When diabetes patients develop CVD, they have a 
poorer prognosis than non-diabetic subjects(97, 98) and are more likely 
to develop cardiomyopathy in the future(99, 100). There is a 3-fold 
increase in stroke mortality in patients with diabetes compared to non-
diabetic subjects(101); with diabetes patients having an increased 
likelihood of severe carotid atherosclerosis compared to subjects without 
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diabetes(102, 103). More than half of participants commencing 
haemodialysis due to end stage renal disease have T2DM(104), and 
these patients’ mortality is shown to be in excess of 20% per year(104) 
with CVD complications as the most common cause of death(105, 106).  
The United Kingdom Prospective Diabetes Study (UKPDS) trial was a 
landmark trial in T2DM designed to investigate the relationship between 
glucose lowering intervention and risk of complications. Subjects were 
randomized to intensive glycaemic treatment vs standard treatment and 
followed prospectively. Standard treatment (n=1138) was diet alone with 
secondary randomization to active glucose lowering treatment if fasting 
plasma glucose was more than 15mmol/L. The intensive group was 
randomized to monotherapy treatment with insulin (n= 1156), 
sulphonylurea (n=1573) or metformin (in those with ideal bodyweight > 
120%, n= 342). After a median follow-up of 10 years, there was a 
reduction of microvascular events of 25% in the intensive group 
(p=0.009). A similar trend was seen in macrovascular outcomes whereby 
intensive glycaemia control resulted in a 16% reduction in combined fatal 
and nonfatal myocardial infarction (MI) and sudden death. This however, 
failed to reach statistical significance with a p value of 0.052. There was 
also no suggestion of reduction in stroke.  
In a 10-years follow up post trial, however, a significant reduction in MI 
and all cause mortality in intensively treated group were observed 
suggesting a legacy effect of early and aggressive glucose lowering 
treatment(107).  
1.2.3 Relationship between treatment of T2DM and CVD mortality 
The majority of patients with untreated T2DM will die from cardiovascular 
disease(108). To reduce this risk, both the American Diabetes 
Association (ADA) and the European Association for The Study of 
Diabetes (EASD) recommends individualized glycaemic control with a 
target HbA1c of 53mmol/mol, targeted blood pressure and lipid control, in 
addition to managing other modifiable risk factors such as smoking and 
obesity(109, 110). 
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Over the last number of years, there have been new classes of 
antihyperglycaemic agents in the market. For the purpose of this thesis, I 
will only discuss the CVD risk with the use of metformin, sulphonylurea, 
thiazolidinediones, and dipeptidyl-peptidase-4 inhibitors. 
1.2.4 General management in T2DM 
Non-pharmacological treatment of T2DM involves extensive lifestyle 
modifications through a structured diabetes self-management education.  
These include practical and effective medical nutrition therapy, limitation 
of alcohol intake, moderate intensity aerobic physical activity (150 
minutes per week), smoking cessation, psychosocial assessment and 
care, and appropriate immunization program(111).  
Antihypertensive treatment should be considered in patients with office-
based elevated blood pressure, with a target of 140/90mmHg in most 
patients; 130/80mmHg in younger patients with evidence of albuminuria 
and/or those with hypertension and one or more additional atherosclerotic 
CV risk factors, as long as no side effects such as hypotension. Other 
measures to reduce blood pressure such as weight loss, reducing sodium 
and increasing potassium intake, moderate alcohol intake, and increased 
physical activity should be emphasized(109). 
Patients age less than 40 years old with CVD risk factors (LDL > 
2.6mmol/l, hypertension, smoking, overweight and obesity) or overt CVD 
(previous cardiovascular events or acute coronary syndrome) need to be 
strongly considered for moderate or high dose statin therapy. Patients 
between the age of 40 to 75 years old with or without CVD risk factors or 
overt CVD are strongly recommended to receive either high intensity or 
moderate intensity statin therapy respectively(109).  
Antiplatelet therapy such as aspirin is recommended as primary 
prevention in participants with increased cardiovascular risk (10-year risk 
> 10%). This would include most men above 50 or women above 60 
years old with at least one additional major risk factor (family history of 
CVD, hypertension, smoking, dyslipidaemia, or albuminuria). Routine 
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screening of coronary artery disease in participants with T2DM is not 
recommended(109). 
1.2.5 Metformin and CVD 
When lifestyle modification alone has not achieved or maintained 
glycaemic target, a patient centered pharmacological treatment should be 
initiated. Metformin monotherapy has a proven evidence base for safety 
and efficacy. It is inexpensive and may reduce CV events(107). After 3 
months, if there is no improvement in HbA1c, a second agent may be 
added to metformin. Choices include sulphonylurea, thiazolidinedione, 
DPP4-inhibitors, SGLT2-inhibitors, GLP receptor agonist or insulin. Triple 
therapy combination with various antihyperglycaemic agents and further 
combination injectable therapy are considered in patients who fail to 
achieve glycaemic target(112).  
The UKPDS Study published in 1998 provided the first robust outcome 
data about the efficacy and safety of the then-licensed T2DM 
treatment(108). Significant reduction of microvascular disease and a non-
statistically significant reduction in myocardial infarction were seen in 
intensively treated participants with sulphonylurea or insulin compared to 
diet alone. In overweight participants (bodyweight greater than 120% 
ideal weight) randomly assigned to metformin, a 39% relative risk 
reduction of fatal and non-fatal myocardial infarction (p=0.01) and a 36% 
relative risk reduction in all cause mortality (p=0.011) were seen(113). In 
the 10-year follow up of UKPDS(107), these metformin-treated obese 
T2DM continued to show reduction in MI (33%) and death from any 
cause (33%). Despite a smaller cohort (n=342 on metformin, n=411 on 
diet alone), lack of lipid lowering drug and modern blood pressure and 
kidney preserving medications, these finding cemented the CV benefit of 
metformin and supported its adoption as a first line treatment in 
T2DM(108).  
Most retrospective analyses of large databases(114-117), which 
suggested the CV benefit of metformin, used sulphonylurea as a 
comparator. Therefore, it is not possible to determine whether the 
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sulphonylurea increased, or metformin decreased, CV outcome in these 
analyses(118). In an example of a prospective study, Hong et al 
randomized 304 T2DM participants with a history of coronary artery 
disease to glipizide or metformin. After 5 years, metformin reduced the 
risk of the composite endpoint (CV death, any cause mortality, MI, non-
fatal stroke, and arterial revascularization) by 46%(119).  Two ongoing 
double-blinded RCTs (Metformin in CABG trial, MetCABG and GIPS-III 
Study) will determine if metformin can reduce infarct size and improve left 
ventricular function after ischaemia-reperfusion injury(118).  A more 
definitive answer may be provided by the ongoing GLINT Study whereby 
12 000 high-risk subjects with dysglycaemia but without overt diabetes 
are randomized to either placebo or metformin for 5 years(118). 
There have been studies evaluating the effect of metformin on CVD 
proxies, most commonly carotid intima media thickness (C-IMT)(118). 
Earlier studies demonstrated small but significant decreases in C-IMT in 
participants treated with metformin compared to placebo(120-122). 
However, in the CAMERA study(123), metformin had no effect on C-IMT 
progression over 18 months in 173 non-diabetic participants although in 
contrast to earlier studies, all subjects in the CAMERA study were on 
statin which will minimize any effect of metformin(118). Previous studies 
have also demonstrated a potential benefit of metformin on endothelial 
function by reducing plasminogen activator inhibitor-1 (PAI-1) after 12-
weeks of treatment compared to placebo(124).    
In summary, the weight of the evidence supports a beneficial effect of 
metformin in reducing CV risk. 
1.2.6 Sulphonylurea and CVD 
Sulphonylureas (SUs) are insulin secretogogues used in T2DM since 
1960s. SUs inhibit ATP-sensitive potassium channel in beta cells, which 
leads to depolarization, opening of calcium-gated channels, and calcium-
dependent release of insulin by exocytosis(125).  
These ATP-sensitive channels are also present in cardiac myocytes, 
which are normally closed. In chronic ischaemia, anaerobic metabolites 
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increase resistance in these channels to ATP, a cardioprotective 
mechanism called pre-conditioning. In the presence of SU, this 
preconditioning adaptation is blunted which is hypothesized to potentially 
contribute to more arrhythmias and larger infarct size with myocardial 
ischaemia(125).  
The first study of SU and CV outcome was the University Group Diabetes 
Program (UGDP) trial in 1971. An older generation SU, tolbutamide was 
associated with increased CV death compared to placebo(126). This 
study was highly criticized as it was not designed nor powered to test the 
hypothesis of inferior CV safety for SU versus placebo(127) and the study 
was confounded by differences in baseline characteristics(125).  
A different SU, Glibenclamide was studied in multiple randomized control 
trials (RCTs) and demonstrated increased cardiac pain compared to 
placebo, impaired cardiac pre-conditioning more than glimepiride and 
placebo (128, 129) and greater in-hospital mortality in participants with 
myocardial infarction compared to gliclazide(130).  
In a recent review article, Rosenstock et al highlighted the discordance 
between the observational studies and RCTs of SU and its cardiovascular 
risk(127).  
Some observational studies demonstrated increased all-cause and CV 
mortality with either SU monotherapy or when SU was combined with 
metformin, as compared to metformin monotherapy(115, 131). A meta-
analysis of observational studies demonstrated that a combination of SU-
metformin therapy versus either monotherapy was associated with 
increased risk of composite CV hospitalization or mortality (RR 1.43; 95% 
CI 1.1 – 1.85), but was not associated with increased risk in either 
outcome alone; which is difficult to explain(132). A nested sub-study 
(n=268) of UKPDS demonstrated an increased risk of diabetes-related 
death (96% increased risk, p=0.04) and all-cause mortality (60% 
increased risk, p=0.04) when metformin was added to SU in obese and 
non-obese participants compared to SU alone. These UKPDS 
investigators commented that this might represent extremes of chances 
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and epidemiological analysis of this possible association showed no 
increased risk in participants treated with SU/metformin combination 
therapy(113).  
There are 15 published RCTs over 15-year period that were ≥72 weeks 
duration and included SU therapy vs active comparator/s or as part as 
treatment strategy(127). The UKPDS analyses involving first and second 
generation SUs, (UKPDS 33 and 80) and demonstrated that 
chlorpropramide, glyburide (glibenclamide) and glipizide were not 
associated with adverse CV events(107, 133). Similarly in the other 14 
RCTs including the A Diabetes Outcome Progression Trial (ADOPT, 
n=4360), and ADVANCE study, a lack of CV adverse outcome was seen 
when SU was used in addition to other antihyperglycaemic agents(127). It 
must be noted that none of these studies had ‘similar target levels’ of 
glycaemic control in the treatment arm or were powered to demonstrate 
CV safety/benefit, and there were inconsistencies in how the CVD events 
were reported and adjudicated(127).  
A dedicated RCT addressing the CV safety question of SUs such as the 
ongoing Cardiovascular Outcome Study of Linagliptin vs Glimepiride 
(CAROLINA) trial will hopefully be informative(127).  
Gliclazide and Gliclazide MR (slow release) are the new-generation SUs 
in the market since early 2000. These medications are licensed to be 
used in Europe but not in the US(112). Compared to the other SUs, 
Gliclazide seems to be the most selective with respect to pancreatic 
receptor stimulation(134). A few observational studies showed 
cardiovascular benefits of gliclazide over other SUs(114, 135, 136) and it 
is the SU of choice in the most recent Netherlands T2DM management 
guidelines(134).  
A recent systematic review and meta-analysis of RCTs comparing 
Gliclazide to other oral anti-diabetic drugs for at least 12 weeks (19 trials, 
n=3083 on gliclazide, n=3155 on other oral anti-diabetic) demonstrated 
lower hypoglycaemia episodes and similar effectiveness compared to 
other agents(134). However, the methodological quality of the RCTs was 
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poor and some were limited due to publication bias. None were designed 
for evaluating cardiovascular outcomes and this will require further 
attention in future RCT(134).  
In summary, SUs are recommended as one of the next choice of second 
line agent after metformin. SUs have high efficacy, low cost and vast user 
experience by clinicians. As it stands, there are discrepancies in the 
evidences from retrospective and prospective studies for the CV 
safety/risk of SU use. A dedicated RCTs (CAROLINA) in currently 
ongoing to address the issue of CV risk/benefit in SU.  
1.2.7 Thiazolidinediones and CVD 
Thiazolidinediones (TZDs) are a group of drugs that exert their 
antihyperglycaemic effect by reducing insulin resistance in the peripheral 
tissue via activation of peroxisome proliferator-activated receptor gamma 
(PPAR-r)(137). Troglitazone was removed from the market due to liver 
toxicity while Rosiglitazone and Pioglitazone carry a significant warning 
about their link to congestive heart failure (CCF)(112).  
Earlier studies demonstrated a potential benefit of TZD on CV risk 
factors. TZD reduces peripheral tissue insulin resistance and this has 
been associated with a reduction in blood pressure(138). A meta-analysis 
of 27 studies demonstrated reduction of systolic blood pressure (SBP) by 
4.7 mmHg and diastolic blood pressure (DBP) by 3.78 mmHg in 
participants on TZD(139). Rosiglitazone reduced triglycerides (TG) by 
39% in one study(140) but in another study, increased TG by 15% while 
Pioglitazone reduces TG by 15%(141). Both Pioglitazone and 
Rosiglitazone have positive effect of increasing high-density lipoprotein 
(HDL) by about 8-15%(141). Both increase LDL by about 16-23% (less 
increase with Pioglitazone) and modify the LDL molecule into a larger, 
less atherogenic form of LDL(141). Both have been associated with a 
reduction in inflammatory markers and increased adiponectin levels, 
which may benefit CV profile as well(142).  
Currently, the benefits of TZDs have been offset by concerns of oedema, 
CCF and long-term cardiovascular outcome. An incidence of oedema of 
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3-5% has been associated with the use of TZD monotherapy, 7.5% in 
combination of TZD and SU (vs 2.1% in SU alone) and 13-16% if using 
TZD in addition to insulin (vs 4-7% in those using insulin alone)(143). The 
incidence of CCF is much lower at less than 1% with Rosiglitazone 
monotherapy and 1.1% for Pioglitazone monotherapy and combination 
with insulin(143).  
In 2007, a meta-analysis of 42 RCTs comparing the use of Rosiglitazone 
with placebo or active comparators of more than 24 weeks was 
published. The main purpose of this study was to assess the effect of this 
agent on cardiovascular outcome. Rosiglitazone was associated with 
significantly increased risk of myocardial infarction with OR 1.43 (95% CI 
1.03 to 1.98, p=0.03) and a borderline significant risk of death from 
cardiovascular causes with OR 1.64 (95% CI 0.98 to 2.74; p=0.06)(144).  
A further prospective study of 5-7 years duration in the RECORD Study 
(Rosiglitazone Evaluated for Cardiovascular Outcome in Oral Agent 
Combination Therapy for Type 2 Diabetes) however, did not suggest an 
increase in major adverse cardiovascular events (MACE) when 
Rosiglitazone was added to either metformin or SU(145). An independent 
re-adjudication of this data by the Duke Clinical Research Institute 
provided reassurance that Rosiglitazone was not associated with excess 
cardiovascular risk(146).   
In the Prospective Pioglitazone Clinical Trial in Macrovascular Events 
(PROACTIVE), 5238 T2DM participants with macrovascular disease were 
randomly assigned to Pioglitazone or placebo for a mean of 34.5 months. 
There was no significant difference in the number of participants from 
each group who had at least one CV event (p=0.095). In the Pioglitazone 
group, there was a reduction in composite all-cause mortality, non-fatal 
MI and stroke by 16% (HR 0.84; 95% CI 0.72 to 0.98, p=0.027)(147). In a 
similar study, there were more cases of bladder neoplasm (14 vs 5), 
fewer cases of breast cancer (3 vs 11) in Pioglitazone group compared to 
placebo; and higher rate of bone fractures (5.1% vs 2.5%) in Pioglitazone 
treated female participants(148). In a more recent meta-analysis, the 
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incidence of bladder cancer in participants treated with Pioglitazone is 
20.8 per 100 000 person years(149).   
In 2010, the European Medicines Agency (EMA) suspended the use of 
Rosiglitazone. In US, it was subjected to enrollment into the Avandia-
Rosiglitazone Medicines Access Program (REMS). The Food and Drug 
Administration (FDA) also issued an update to the Guidance for Industry 
in 2008 whereby prior to submission for new drug application, sponsors 
must compare the incidence of important cardiovascular events occurring 
with the investigational agent to the incidence of the same types of events 
occurring with the control group to show that the upper bound of the two-
sided 95 percent confidence interval for the estimated risk ratio is less 
than 1.8. If the estimated increased risk is between 1.3 and 1.8, a post-
marketing trial will be necessary to show that the upper bound of the two-
sided 95 percent confidence interval for the estimated risk ratio is less 
than 1.3. If the premarketing application contains clinical data with 
estimated increased risk less than 1.3, a post-marketing cardiovascular 
trial generally may not be necessary(150).  
In June 2013, the FDA re-evaluated the CV risk of Rosiglitazone based 
on the RECORD Trial (Rosiglitazone Evaluated for Cardiovascular 
Outcomes and Regulation of Glycaemia in Diabetes)(145). This 
multicentre, open labeled study randomly assigned 4447 poorly controlled 
T2DM patients to either Rosiglitazone or SU in addition to 1st line 
treatment. The hazard ratios in patients receiving Rosiglitazone were 0.95 
for the composite end point for CV death, MI or stroke; 0.9 for CV death; 
1.13 for MI; 0.79 for stroke; and 0.86 for all-cause death. None were 
statistically significant. Based on these non-inferiority findings, in May 
2014, the FDA removed certain restrictions in prescribing Rosiglitazone. 
In summary, Rosiglitazone and Pioglitazone are effective 
antihyperglycaemic drugs with additional benefits on blood pressure, lipid 
profile and inflammatory markers. Long-term studies and meta-analysis 
suggested increase risk of oedema, heart failure and possible risk of 
myocardial infarction and death. Previously, CV outcome was not a 
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requirement for drug approval but the Rosiglitazone experience has 
changed this. While this requirement is beneficial for patient safety, 
evaluation of CV outcome will potentially require higher cost, longer-term 
studies that will have an impact of the medication’s value upon entering 
market.  
1.2.8 Dipeptidyl-peptidase-4 inhibitors (DPP4i) and CVD 
One of the newer classes of antihyperglycaemic medications are incretin-
based medications. These include DPP4i and Glucagon like peptide-1 
agonist (GLP1a). Glucagon like peptide 1 (GLP1) is secreted by intestinal 
cells and rapidly deactivated by DPP4 enzyme. Through specific 
receptors on pancreatic β-cells, GLP1 provides an additional stimulus to 
insulin secretion after oral glucose ingestion, that is not present with 
intravenous glucose infusion. It is well documented that patients with 
diabetes have impairment in the GLP1 response following ingestion of 
food(151).  DPP4i increases endogenous GLP1 by inhibiting the function 
of the deactivating enzyme DPP4. Sitagliptin, Saxagliptin, and Linagliptin 
are among the DPP4i available in the market today. DPP4i reduce HbA1c 
by approximately 0.5 to 1% and are weight neutral(3).   
Earlier meta-analysis of RCTs in participants who were randomly 
assigned Saxagliptin in a broad drug development program demonstrated 
no increased risk of CV death, MI or stroke, with a relative risk reduction 
of 0.44 (95% CI 0.24-0.82)(152). Another meta-analysis of 41 RCTs of 
DPP4i use in T2DM for more than 12 weeks demonstrated a non-
significant reduction in CV death and all cause of death with a relative risk 
of 0.76 (0.46-1.28) and 0.78 (0.4-1.51) respectively(153).  
On the background of the new FDA regulation, the EXAMINE Study 
evaluated the CV outcome in 5380 T2DM participants with acute 
coronary syndrome (ACS) randomized to Alogliptin or placebo in addition 
to existing antihyperglycaemic and CV drug therapy. After a median 
follow up of 18 months (up to 40 months), the hazard ratio for composite 
of death from CV causes, nonfatal MI, or nonfatal stroke was 0.96 
(p<0.001 for non-inferiority)(154). Similarly, the SAVOR-TIMI study 
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evaluated the CV outcome in 16 492 T2DM participants who had a 
history of, or were at risk for CV events; randomly assigned to either 
Saxagliptin or placebo over a median of 2.1 years. There were no 
significant differences in the composite of CV death, MI, or ischaemic 
stroke (primary outcome) with HR of 1.0 with Saxagliptin (0.89-1.22, 
p=0.99 for superiority, p<0.001 for non-inferiority). Unexpectedly, more 
participants in the Saxagliptin group were hospitalized for heart failure 
with a HR of 1.27 (1.07-1.51, p=0.007)(155). The increase in risk was 
highest among participants with elevated level of natriuretic peptide, 
previous heart failure, or chronic kidney disease. From a safety viewpoint, 
more patients in the Saxagliptin group (15.3%) had hypoglycaemic events 
compared to the placebo group (13.4%, p<0.001). There were similar risk 
of cancers, pancreatitis, haematological disorders, infections, skin 
reactions, bone fractures and abnormal liver function.  
Both of these studies overturned the previous meta-analyses showing CV 
benefit of DPP4i, and instead demonstrated a non-inferiority of DPP4i 
with regards to CV safety, compared with placebo, when added to usual 
diabetes care(108).  
In summary, DPP4i improve HbA1c, are well tolerated, and with a weight 
neutral effect, a welcome addition as a new class of antihyperglycaemic 
agent. The long-term effects of DPP4i on CV risk or benefit are still 
unclear. An alternative method of identifying this risk or benefit is needed 
in order to prevent similar experience seen with Rosiglitazone. There are 
at least 4 other ongoing longer term RCTs evaluating CV outcome in 
DPP4i (TECOS, CANVAS, BI10773, and CAROLINA) and hopefully 
these will shed further light on potential risk and benefit of this group of 
antihyperglycaemic drugs with longer term use. 
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1.2.9 Endothelial Dysfunction in T2DM 
Insulin resistance and hyperinsulinaemia, adipose tissue, oxidized LDL, 
reactive oxygen species and advanced glycation end product (AGE) are 
factors affecting endothelial function in T2DM. 
Insulin resistance is common in T2DM and it can be present for many 
years before any abnormality of plasma glucose(156). It is defined as 
decreased ability of insulin to promote glucose uptake in skeletal muscle 
and adipose tissue and to suppress hepatic glucose output. Animal and 
human studies of insulin resistance have demonstrated the role of insulin 
resistance in endothelial dysfunction (157) which is a precursor to 
atherosclerosis(68).  
Insulin resistance may be linked to endothelial dysfunction by a numbers 
of mechanisms (Figure 1-3). Increased adiposity results in increased 
production of free fatty acids (FFA) due to increased lipolysis. FFA 
decrease glucose oxidation and inhibit mobilization of GLUT4 (major 
glucose transporter), which further inhibits insulin-mediated glucose 
uptake(158).  
Adipose tissue also produces TNF-α and resistin which further mediates 
insulin resistance(159). Over time, these lead to further development of 
metabolic syndrome characteristics, such as development of 
hypertension, hyperuricaemia, low HDL cholesterol, production of plasma 
Plasminogen Activator Inhibitor 1 (PAI-1) mediated thrombotic tendency 
and elevated of oxidation-prone, small dense LDL cholesterol(160). 
These components of metabolic syndrome increase vascular production 
of reactive oxygen species which further worsen endothelial 
dysfunction(160). Hyperinsulinaemia also enhances neutrophil 
transendothelial migration, which leads to increased production of platelet 
endothelial cell adhesion molecule-1 (PECAM-1) but not ICAM-1, P-
selectin or E-selectin(161). 
Oxidized LDL cholesterol disrupts the cholesterol-rich invaginations on 
endothelial cells and vascular smooth muscle cells called caveoloe(157). 
Endothelial nitric-oxide synthase (eNOS) interacts with caveoloe and 
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decreases vasoconstrictive effect of angiotensin II and endothelin. The 
disruption of caveoloe is thought to be the mechanism that reduces 
eNOS availability and contributes to endothelial dysfunction. HDL 
cholesterol however prevents the oxidized LDL-mediated decrease 
cholesterol in caveoloe and donates cholesterol to the caveoloe complex, 
which further improves the endothelial responsiveness to Acetylcholine 
(Ach)(157).  
 
Figure 1-3: Progression of insulin resistance to T2DM parallels the progression 
of endothelial dysfunction to atherosclerosis. Adapted from Hsueh at al Am J 
Med.2004;117:109-117. 
 
Advanced glycation end-product (AGE) consists of protein or lipids that 
became glycated after exposure to a hyperglycaemic state as in diabetes 
mellitus. Mechanisms accompanying AGE mediated inflammation are 
likely multifactorial. Besides promoting oxidized-LDL, through the 
diacylglycerol (DAG)-protein kinase C (PKC) pathway, AGE lead to 
superoxide particles that inactivate NO production which leads to 
accelerated atherosclerosis(162).  
These multiple insults on endothelial cells results in lost of cell integrity, 
cell senescence and further apoptosis(163, 164). Loss of cell integrity 
produces a paradoxical constriction instead of vasodilatation when 
endothelial cells exposed to increasing amount of Ach. Additionally, 
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through a complex interaction involving mechanical stretch of β1-integrin 
signaling pathway, an apoptotic process is induced(68).   
Apoptosis leads to detachment of endothelial cells, which are released 
into the bloodstream and can be recognized and measured as circulating 
endothelial cells irrespective of glucose level(165). Besides endothelial 
cells, endothelial microparticles released from the intact cells following 
apoptosis act as a powerful pro-coagulant and have been shown to be 
predictive of coronary artery lesion, and more significant independent risk 
factors than duration of diabetes, lipid levels and presence of 
hypertension(166). Arterial denudation is the end result of endothelial 
cells apoptosis. This process triggers smooth muscle proliferation, 
migration and matrix secretion which are pro-atherosclerotic(68).  
The capabilities of EPC to home in on ischaemic sites, differentiate into 
mature endothelial cells, and form a cellular patch at sites of endothelial 
injury contributes directly to homeostasis and repair of endothelial 
layer(68). This reparatory process is fundamental in re-establishing 
vessel integrity. With almost all risk factors for atherosclerosis having 
been associated with decrease and/or dysfunction of EPC, it plays a 
major role in cardiovascular biology and provides a mirror image of 
cardiovascular health(167).  
In summary, the pathogenesis of endothelial dysfunction in T2DM is 
multifactorial. The insults to endothelial cells began with the development 
of insulin resistance before diabetes is diagnosed. The end results are 
endothelial cells apoptosis and arterial denudation with atherosclerosis as 
a consequence. There is increasing evidence that EPC provides an 
essential role in endothelial cell reparatory process and improvement of 
EPC numbers and/or function may help to reduce the risk of 
atherosclerosis.  
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1.2.10 EPC in T2DM 
Multiple studies have demonstrated a reduction in the number of EPC by 
up to 40% and 44% in T2DM and T1DM patients compared to controls. 
Diabetes also affects the angiogenic function of EPC in vitro especially in 
the formation and participation of endothelial tubule formation (42, 168, 
169).  
Some researches suggest that level of EPC may fluctuate as the patient 
progresses through stages of diabetes. In a study involving 425 subjects 
with various degree of glucose metabolism status (normal glycaemia to 
diabetes), and with different diabetes duration, demonstrated a significant 
nadir of CD34+ EPC at the time of diagnosis of T2DM, partial recovery in 
the subsequent years (up to 19 years post diagnosis), followed by 
exhaustion of bone marrow reserve in the longer term (> 20 years post 
diagnosis) (170).  Using multiple linear regression models, the reduction 
in EPC is partly attributed to aging, concomitant risk factors or CVD and 
not entirely to their carbohydrate metabolism status or diabetes duration. 
In addition to weak marrow mobilization, decreased proliferation and 
shortened survival, diabetic EPCs demonstrated impairment in 
proliferation, adhesion, and migration at the damaged endothelial 
cells(171).  
The mechanisms underlying reduction of EPC in diabetes patients seems 
to include reduced bone marrow mobilization, reduced proliferation and 
shortened survival of EPC(172). 
Central to reduced marrow mobilization of EPC in diabetes is a defect in 
marrow stimulation following ischaemia. Tissue ischaemia is considered 
the strongest stimulus for EPC release from bone marrow(172). The 
hypoxia sensing system HIF-1 (hypoxia-inducible factor-1) consists of 
heterodimeric transcription factor composed of α (HIF-1 α) and β (HIF-1 
β) subunit. In cellular hypoxia, the normal degradation process of HIF-1 α 
is attenuated allowing dimerization with HIF-1 β resulting in active HIF-1. 
This will bind to enhancer DNA regions and promotes transcription of 
oxygen sensible genes that encode, among others VEGF, SDF1 α and 
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erythropoietin (EPO)(173). These growth factors stimulate EPCs into the 
circulation by transendothelial migration, and further recruitment is 
mediated by hypoxic gradient via HIF-1 induced SDF1 expression(67). In 
a streptozotocin-diabetes rat model with hind-limb ischaemia, stimulation 
of EPC mobilization following ischaemia was impaired. Additionally, these 
diabetes rats had altered release of SDF-1, VEGF and inability to 
upregulate muscle HIF-1α compared to control rats(174). This HIF-1α – 
SDF-1 – VEGF hypoxia responsive system has been shown to mediate 
adhesion, migration and homing of circulating progenitor cells to 
ischaemic tissue(67). The weak angiogenic response through this system 
in the setting of tissue ischaemia results in the inability to mobilise the 
progenitor cells necessary for new vessel formation(172).  
Reactive oxygen species (ROS) have been implicated in the deregulation 
of HIF-1α. Further on, inhibition of these ROS by N-Acetylcysteine (NAC) 
in diabetic mice with ischaemia restored the endothelial growth factors 
level to non-diabetic level and up-regulates the number of EPC(175).  
Insulin treatment in T2DM may increase the number of EPC as 
demonstrated in an in vivo study involving poorly controlled diabetes 
patients (n=23). In this study, EPC numbers improved by 65% following 
insulin treatment, and this did not correlate with the improvement in 
HbA1c and fasting glucose. Subjects were further screened for SDF1 
genotypes and following multivariate analysis, SDF1-3’A/G genotype was 
an independent predictor of EPC mobilization following insulin 
therapy(176). Nevertheless, it can be postulated that improvement in 
metabolic control may induce more efficient stimulation of EPC-mediated 
neovascularization(68).  
Another mechanism underlying weak marrow stimulation is alteration of 
the PI3K/Akt pathway in patients with diabetes. Diabetes leads to 
hyperglycaemia and this generates the non-enzymatic glycation of protein 
and lipids (AGE), which accumulate in the vessel wall. AGE binds to its 
transmembrane receptor (RAGE) producing a cascade of cellular events 
involving protein kinase C (PKC) and mitogen-activated protein kinase 
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(MAP), which leads to cellular dysfunction(177). Diacyglycerol (DAG) and 
PKC are essential intracellular signaling molecules responsible for 
vascular permeability, vasodilator release, endothelial activation and 
growth factor signaling.  Pathological activation of PKC by DAG occurs in 
hyperglycaemia resulting in increased permeability of vessel wall, altered 
NO regulation, increase leukocyte adhesion, and enhanced expression of 
growth factors (VEGF, TGF-β, ET-1)(177). These intracellular activations 
of PKC and MAP are part of a bigger system of intracellular signaling 
mediated by P13K/Akt pathway and this pathway have been suggested to 
mediate EPC endothelial migration(41).  
Hyperglycaemia also alters leukocyte and endothelial function through 
the production of reactive oxygen species (ROS)(178) and may have a 
role in the apoptosis of EPC. In an in vitro study, EPC from healthy 
donors were exposed to hyperglycaemia and normoglycaemia state. 
Hyperglycaemia state resulted in increase in apoptosis and reduction in 
EPC proliferation compared to normoglycaemia state. This oxidative 
stress also plays a significant role in damaging the interaction between 
vascular wall and EPCs while induction of the antioxidant, 
hemeoxygenase-1 (HO-1) gene partially reverses this process(179). 
Elevated C-reactive protein (CRP) and systemic hypoxia have been 
shown to downregulate EPC by enhancing apoptosis(180, 181) while 
gene expression of NADPH oxidase, which is a major source of ROS, is 
increased in EPC precursor monocytes from T2DM patients depending 
on glycaemic control(182).  
Hyperglycaemia state in diabetes has been shown to cause functional 
impairment as reflected by reduction in NO production and 
metalloproteinase (MMP)-9 activity, as well as impairment in migration 
and integrative capacities(183). The evidence in vivo is not conclusive 
and needs further investigations(68). A study involving subjects with 
varying degree of diabetes (IFG, IGT and T2DM) including non-diabetes 
subjects demonstrated an inverse relationship between EPC apoptosis 
and peripheral EPC level with no difference in the apoptotic rate between 
diabetes and non-diabetes subjects(170).  
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Metabolic syndrome (MetS) and insulin resistance in diabetes reduces 
EPC numbers especially CD34+ progenitor cells. In a cross-sectional 
study of 214 subjects with variable degree of CV risk, all components of 
MetS has a negative impact on the number of CD34+ cells and clusters of 
these factors act synergistically to reduce the numbers of these cells. In a 
subgroup analysis of 125 subjects, the measurement of insulin resistance 
homeostatic model arrangement (HOMA) was negatively correlated with 
CD34+ cell counts indicating potential molecular mechanisms in patients 
at risk of diabetes(38). Furthermore, insulin resistance state in metabolic 
syndrome is characterized by defective activation of P13K/Akt pathway 
and decrease endothelial NO activity which are essential for EPC 
mobilization and function(172).  
In summary, diabetes affects the release, mobilization, function and 
survival of EPC through various pathways. Hyperglycaemia, 
hyperinsulinaemia, oxidative stress and metabolic syndrome are some of 
the known pathological changes common in diabetes, and these factors 
are having a negative impact on EPC.  
1.2.11 Effect of Anti-diabetic Treatment on EPC 
Anti-diabetes medications have been shown to have a positive effect on 
EPCs.  
1.2.11.1 Sitagliptin and EPC 
Fadini et al evaluated the effect of Sitagliptin for 4 weeks compared to no 
treatment (control) on the level of EPC in T2DM patients already treated 
with metformin and/or secretagogues(184). EPC were counted using 
flow-cytometry and identified with their surface marker CD34+KDR+ cells.  
Total CD34+ count, expression of CXCR4, SDF1a, VEGF, MCP-1, NO 
and plasma DPP4 were measured.  
In this study, there was two-fold increased in circulating EPC following 
Sitagliptin therapy compared with control. Also there was an increased 
plasma concentration of SDF1a by 50% and a reduction in plasma 
Monocyte Chemoattractant Protein-1 (MCP-1) by 25% in Sitagliptin group 
compared to no treatment. There were no significant changes seen in NO 
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level or the level of CD34+ cells counts in both groups. SDF1a receptor 
CXCR4 were only expressed on 17% of CD34+ cells compared to 63% of 
CD34+KDR+ cells which explains the differential effect of Sitagliptin on 
either cells. It is postulated that this beneficial effect on EPC was 
mediated by augmenting the level of SDF-1α, which has been shown to 
be essential in EPC mobilization from bone marrow, migration, 
proliferation, and survival (65-67, 184). 
1.2.11.2 Saxagliptin and Proangiogenic Cells (PACs) 
Poncina et al evaluated the effects of Saxagliptin on the pro-angiogenic 
cells (PAC) including cells considered to be EPC, in a cross-sectional 
study involving healthy volunteers and patients with T2DM(185). PACs 
isolated from peripheral blood were incubated after day 4 with an 
equivalent therapeutic 5mg dose of Saxagliptin and/or SDF1α in-vitro. 
Proliferation, clonogenesis, adhesion, migration and tube formation were 
analyzed. Gene expressions analyses on PACs were performed in both 
groups at baseline. The effect of Saxagliptin and/or SDF1α on PACs 
gene expression was performed on a subgroup of PACs CD14+ and 
CD14- from healthy volunteers (n=20) only. Finally, a separate in-vivo 
study assessing the pro-angiogenic effects of Saxagliptin was performed 
using PACs isolated from T2DM patients who had been treated with 
Saxagliptin (>4 months at enrolment, n=5) and this was compared to 
T2DM patients not treated with Saxagliptin.  
In this study(185), Saxagliptin and/or SDF1-α did not restore PACs 
colony formation in patients with T2DM but tended to increase the colony 
numbers in healthy controls. Similarly, co-treatment with SDF1-α 
promoted haematopoetic clonogenesis in healthy controls but not in 
PACs from T2DM patients. The different findings in these two groups may 
be related to lower baseline gene expression of CDKN1A and BCL2 
genes in PACs from T2DM subjects. Saxagliptin was also shown to have 
no effect on the percentage of cells staining with acLDL+Lectin+(185) 
Poncina et al used the Human Umbilical Vein Endothelial Cell (HUVEC) 
to assess adhesion capacity. Saxagliptin in the presence of SDF1-α 
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increased PACs adhesion in T2DM patients while it had no effect on 
PACs from healthy volunteers. There was no difference in PACs cells 
adhesion capacity when treated with Saxagliptin or SDF1-α alone in 
patients with T2DM(185). This indicates the important role of available 
SDF1-α in order to modulate the adhesion function of PACs.  
Poncina et al also demonstrated that PACs from diabetic subjects had 
increased expression of DPP4 gene with lower expression of adhesion 
genes such as Vascular Adhesion Molecule 1 (VCAM1), Intercellular 
Adhesion Molecule 1 (ICAM1) and Integrin Subunit Beta 2 (ITGB2) 
compared to healthy control PACs. This may translate into an increase in 
DPP4 activity in-vivo in patients with T2DM independent of improvement 
in glycaemic control as demonstrated by Fadini et al(186). With SDF1-α 
acting as a physiological substrate for DPP4, an increase in DPP4 activity 
in PACs from T2DM subjects inactivates SDF1a (184). 
1.2.11.3 Metformin, Gliclazide and EPC  
Chen et al randomized 47 new T2DM patients to either Metformin 
monotherapy or Metformin and Gliclazide MR dual therapy for 16 weeks. 
Early dual therapy significantly improved circulating EPC numbers 
measured using flow cytometry and cultured EPC stained positive for 
acLDL and Lectin. Dual therapy also improved EPC migratory capacity 
and plasma markers of oxidative stress. There was no difference in the 
numbers of EPC colony forming unit in both groups(187). Metformin 
exerts its effect through the activation of AMP-activated protein kinase 
(AMPK) pathway(188, 189). Nitric oxide (NO) is essential in EPC 
mobilization and the AMPK pathway has been linked to the activation of 
endothelial cells stimulated endothelial nitric oxide synthesis (eNOS) and 
NO production(190). Gliclazide is a second-generation sulfonylurea with 
azabicyclo-octyl ring, described as having antioxidant property and has 
been shown to significantly improve EPC numbers and endothelial 
function in newly diagnosed T2DM patients compared to baseline(191). 
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1.2.11.4 Pioglitazone and EPC 
Esposito et al examined the effects of Pioglitazone or Metformin on EPCs 
and markers of endothelial injury Endothelial Microparticles (EMPs), in 
110 newly diagnosed T2DM. There were increased in the numbers of 
EPC with a reduction EMP in the Pioglitazone group compared to 
Metformin group after 24 weeks of therapy(192). It is postulated that by 
suppressing inflammation and improving the level of adiponectin, 
Pioglitazone may have a positive effect on EPC(193-195). 
1.2.12 Summary 
The prevalence of T2DM is increasing in Ireland and around the world. 
Multifactorial alterations in diabetes contribute to endothelial dysfunction 
that leads to atherosclerosis and macrovascular complications. 
Aggressive glycaemic, lifestyle modification, antihypertensive, statin and 
antiplatelet are essential. In general, anti-diabetic medications have 
positive effects on EPC. Metformin reduces CV events while the 
Sulphonylureas carry a neutral CV risk. DPP4i are one of the newer 
classes of antidiabetic medication with no CV outcome data at the 
initiation of this research. While the use of Pioglitazone appeared to be 
safe, the withdrawal of Rosiglitazone suggest a need for identification of 
CV risk or benefit prior entering the market, either with a long term study 
or by utilizing an appropriate CV marker. As EPC numbers predicts the 
future risk of CVD, estimation of EPC number may have a role in fulfilling 
this need in patients with T2DM.  
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1.3 Arterial Stiffness  
As well as acting as a conduit for blood flow from the heart, arteries, and 
in particular the aorta, act as a ‘dampening mechanism’, to reduce the 
effect of myocardial contraction on changes in blood pressure and 
therefore resulting in a more steady flow of blood into peripheral 
tissue(196).  
Arterial stiffness is an age-related process, that is a shared consequence 
of many diseases such as diabetes, hypertension, metabolic syndrome 
and chronic kidney disease among others(197). As aorta stiffens, it is less 
able to accommodate volumes of blood from the left ventricle, and this 
dampening mechanism is attenuated resulting in left ventricular 
hypertrophy and fibrosis, fluctuation of blood pressure, reduction in vessel 
wall sheer stress and production of NO, and further promotes 
development of atheromatous plaques(196).  Arterial stiffness has been 
shown to be a strong independent predictor of future CV events and all 
cause mortality in general population(6).  
1.3.1 Assessment of Arterial Stiffness 
Measurement of pulse wave velocity (PWV) especially the carotid-femoral 
PWV (also known as aortic PWV) is considered the gold standard in 
laboratory assessment of arterial stiffness(196, 198). With ventricular 
contraction, a pressure pulse is generated and this is propagated along 
the arterial tree. The speed of the pulse is determined by the geometric 
and elastic properties of the arterial wall and majority of this ‘buffering’ 
occurs in the aorta. A stiff artery results in an increase in pulse speed 
compared to an elastic artery. If the time interval between the foot of the 
pulse wave is measured transcutaneously at two different sites and the 
distance between the two sites is known, PWV can be calculated as: 
velocity (m/s) = distance (m)/time (s)(196). 
PWV is non-invasive, easy to perform, reproducible, and has been shown 
to predict CV events in large epidemiological and clinical studies(198-
200). Two probes or automated cuffs are placed around the carotid at the 
neck and femoral artery at the groin. Using software from Complior®, 
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SphygmoCor® or Vicorder®, waveforms from common carotid and 
femoral artery will be generated (Figure 1-4). Time delay (or transit time) 
between the feet of both waveforms is measured and by measuring the 
distance between the two waveforms, a PWV is generated(198).  
 
Figure 1-4 Measurement of carotid femoral Pulse Wave Velocity (PWV). 
Δt = transit time or time delay, ΔL= length or distance. Adapted from 
Laurent et al European Heart Journal (2006) 27, 2588–2605. DOI: 
10.1093/eurheartj/ehl254 
 
Recently, recommendations have been published in order to optimize 
PWV measurements(196, 201). It should be performed in a quiet room 
with stable temperature. Measurements should be performed in a supine 
position after 10 minutes of rest, preferably using the right common 
carotid and right common femoral artery. If repeated measurement is 
needed, it should be done at the same time of the day to avoid diurnal 
variation. Subjects should refrain from meals, smoking or caffeine within 3 
hours of measurement, and from speaking or sleeping during 
measurements.  
Data should be the mean of recorded pulse waves during at least one 
respiratory cycle (about 5-6s). Carotid femoral distance should be 
measured in a straight line. Measurement should be taken twice and the 
mean of it is calculated. If the differences between the two measurements 
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are more than 0.5m/s, perform a third measurement and the median 
value should be used(196, 201).  
Despite being considered as a gold standard measurement of arterial 
stiffness, measurement of PWV in clinical practice is hampered by the 
lack of method standardization and reference value(202). In 2007, the 
European Society of Hypertension (ESH) and European Society of 
Cardiology recommended 12m/s as a threshold that signified alteration of 
arterial function in middle-aged hypertensive patients(203). However, this 
was based on epidemiological studies and could not take into account 
multiple factors influencing PWV(202). The most important factors 
consistently showing independent association with PWV are age and 
blood pressure(204, 205). A more recent consensus statement however 
reduced the estimate threshold to 10m/s by taking into account the 20% 
shorter true anatomical distance travelled by the pressure wave(201).  
In 2010, The Arterial Stiffness Collaboration Group published the 
reference value for carotid femoral PWV for normal European population 
with no CV risk factors and proposed a reference value in population with 
various risk factors based on age and blood pressure categories(202). 
This consensus included 13 centres in 8 European countries with a total 
of 11 092 subjects (Table 1-1). Following that, Van Bortel et al published 
a new guideline that categorizes levels of aortic PVW associated with 
increased CV risk(201).  
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Table 1-1 Distribution of PWV values (m/s) in the reference value 
population (11 092 subjects) according to age and blood pressure 
category. SD (standard deviation), 10pc (the upper limit of 10th 
percentile), 90pc (the lower limit of 90th percentile), HT (hypertension). 
(Adapted from Eur Heart J 2010, Vol 31, Issue 19, 2338-50, DOI 
10.1093/eurheartj/ehq165) 
 
1.3.2 Arterial Stiffness, PWV and T2DM: Clinical Studies 
In 2014, Prenner et al published the first systematic review of studies 
evaluating arterial stiffness in patients with diabetes mellitus(197). 
Besides carotid femoral PWV (cfPWV), other methods used to assess 
arterial stiffness were carotid-radial PWV (crPWV), carotid-ankle PVW 
(caPWV), pulse pressure (pp), and augmentation index (Aix). 
Several studies have demonstrated increased in PWV in patients with 
diabetes when compared to non-diabetic controls(206-208). Diabetes 
patients have increased PWV measured at 4 segments of main vessels 
(heart-carotid, heart femoral, heart-brachial, and femoral-ankle) when 
compared to control, with greater effects of diabetes and age on larger 
vessels (heart-carotid and heart femoral)(206). Additionally, they also 
have an accelerated progression of arterial stiffness compared to normal 
subjects as highlighted in a study involving 169 subjects (n=57 diabetics, 
n=112 non-diabetics), whereby on average, diabetes subjects had PWVs 
(cfPWV, crPWV) readings similar to non-diabetics who were 15 years 
older(207). Evidence for this accelerated process is further provided by a 
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prospective studies in metabolic syndrome subjects, a known 
predisposing factor for T2DM development; whereby an increased in 
PWV seen with increasing number of metabolic syndrome components, 
over 6 and 9 years follow up(209, 210).   
Studies examining the impact of arterial stiffness in diabetes have 
demonstrated links to end-organ damages including nephropathy, 
retinopathy, autonomic dysfunction/neuropathy, cognitive dysfunction and 
stroke(197). 
Albuminuria precedes diabetic nephropathy, carries a poor prognostic risk 
and is an independent predictor of all-cause and cardiovascular mortality 
in patients with diabetes(211, 212). Smith el al evaluated the relationship 
between cfPWV and varying degree of albuminuria in 134 T2DM patients. 
Patients with raised albumin creatinine ratio (ACR) had stiffer arteries as 
demonstrated by higher cfPWV. There was a negative univariate 
association between cfPWV and GFR, suggestive of early changes in the 
viscoelastic property of large arteries well before the onset of overt 
diabetic nephropathy(213). Additionally, the independent association 
between aortic PWV with the level of albuminuria was demonstrated by 
Ishimura et al in a study involving 167 T2DM patients(214). Kimoto et al 
also demonstrated this independent association in larger study involving 
434 T2DM patients and 192 healthy controls whereby stepwise 
progression of large artery stiffness was seen as GFR worsened after 
adjustment for confounders(206). The worsening GFR will lead to end-
stage renal disease (ESRD) and aortic stiffness has been shown to 
predict mortality in subjects who progress to ESRD(200).  
Another predictor of CV mortality in T2DM is the presence of diabetic 
retinopathy(215). In a cross-sectional study involving 494 T2DM patients, 
heart-femoral PWV (hfPWV) was significantly higher in patients with 
retinopathy compared to patients without retinopathy. There was also an 
independent association between quartile of hfPWV with retinopathy after 
adjustment for confounders(216). 
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Autonomic neuropathy is also associated with arterial stiffness and is a 
predictor of CV mortality(217). In a cross sectional study involving 45 
T2DM patients and control subjects, PWV and autonomic function tests 
were performed. There was increase in central PWV in diabetes patients 
compared to controls with an independent positive correlation between 
PVW and autonomic neuropathy score(218). Larger studies involving 676 
T1DM patients compared to controls demonstrated an increase in PWV 
with degree of cardiac autonomic neuropathy measured using heart-rate-
variability (HRV) and the relationship persisted after adjustment for 
confounders(219).  
Brain white matter lesions (WML) are associated with an increased risk of 
stroke(220). Laugesen et al investigated the association between cfPWV 
and the degree of WML in 89 T2DM patients compared with 89 controls. 
In this study, cfPWV was higher in diabetes patients despite having 
excellent glycaemic control and lower blood pressure and cholesterol 
profile compared to controls. The odds of having higher degree of WML in 
the brain was increased by 30% per 1m/s increased in cfPWV 
independent of potential confounders suggestive a potential role of PWV 
evaluation in risk stratification for stroke(221).  
1.3.3 EPC and PWV in Diabetes Patients 
There have been some limited studies evaluating the relationship 
between EPC and PWV in patients with diabetes.  
Palombo et al used multiple measures of arterial stiffness (including 
cfPWV) and measured circulating EPC in 16 uncomplicated young T1DM 
patients and 26 controls. EPC numbers and cfPWV were lower in T1DM 
patients compared to controls. However, there was no significant 
relationship between circulating EPC numbers and cfPWV in the 
univariate analysis(222).  
Yue at al evaluated EPC numbers and brachial-ankle PWV (baPWV) in 
234 T2DM patients and 121 controls. Poorly controlled diabetes patients 
had lower EPC counts and higher baPWV compared to patients with 
good glycaemic control. Circulating EPCs were negatively correlated with 
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baPWV while multivariate analysis demonstrated HbA1c and EPC count 
as independent predictors of baPWV(223).  
Protopsaltis et al evaluated cfPWV and EPC in 53 subjects with pre-
diabetes. In this study, there was no correlation between cfPWV and EPC 
numbers(224).  
In summary, arterial stiffness is an important predictor of CV disease 
especially in patients with diabetes. Measurement of carotid-femoral PWV 
is considered the gold standard in the evaluation of arterial stiffness and 
the latest evidence on PWV reference range and its relationship with 
CVD will strengthen its use in risk factor evaluation. Several clinical 
studies have proven the link between diabetes complications, arterial 
stiffness and CVD. However, there are limited data on the association 
between PVW and EPC in patients with diabetes.  
1.3.4 Summary 
Arterial stiffness is common in diabetes and is a strong independent 
predictor of future CV events and mortality. PWV is considered the gold 
standard in the evaluation of arterial stiffness. It is not until recently that 
we have a minimum PWV threshold. Arterial stiffness is more prevalent in 
diabetics compared to non-diabetics. It predicts the development of 
microalbuminuria, retinopathy, neuropathy and stroke.  
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1.4 Taurine 
1.4.1 Discovery and significance of Taurine 
Taurine, 2-aminoethanesulfonate is a free amino acid, present 
ubiquitously in millimolar concentrations in all mammalian tissues(9), with 
highest concentration in the heart, retina, brain, skeletal muscle, white 
blood cells and platelet(225).  
The physiological role of taurine became more evident when cats and 
primates fed with taurine-free diet develop retinal degeneration(226, 227). 
Similarly, taurine supplementation in rats prevents conjunctiva, corneal 
and retinal changes typical of Xerophthalmia(228).  
Humans have very low capacity to synthesize taurine and subsequently 
rely on dietary taurine, mostly from seafood and meat. A WHO worldwide 
epidemiological study demonstrated an inverse correlation between 
urinary taurine excretion, surrogate marker for dietary taurine intake and 
mortality rate caused by ischaemic heart disease(8). 
Taurine has an essential role in antioxidation, modulation of ion 
movement(229), osmoregulation(230), modulation of neurotransmitters 
and conjugation of bile acids(231). In various animal models, the 
antioxidant property of taurine is essential to protect from diabetes and 
complications(9).  
Taurine acts poorly with superoxide, peroxide and hydroxyl radicals. In 
the presence of activated neutrophils, Taurine reacts at 1:1 ratio with the 
hydrogen peroxide-myeloperoxidase-chloride (HCIO) system forming 
taurine chloramine, acting as a scavenger for acid(232) in many cell types 
including myocardium (Figure 1-5).  
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Figure 1-5: The beneficial action of Taurine against hyperglycaemia 
induced endothelial dysfunction. Taurine can inhibit AGE production, 
oxidized LDL (oxLDL), production through scavenging melondialdehyde 
(MDA) and hypochlorous acid (HCIO), HCIO-dependent NO reduction, 
and leukocyte-endothelium interaction. (Adapted from T.Ito et al. Amino 
Acids (2012) 42:1529-1539) 
 
Oxidation of LDL is a myeloperoxidases (MPO) driven process, resulting 
in vasoconstriction by consumption of nitric oxide (NO)(233). It has been 
shown to be an important inflammatory marker in hyperglycaemia-
mediated vascular inflammation(234), coronary artery disease and may 
have implications for atherosclerosis(235). By decreasing the carbonyl 
group production and reacting to aldehyde(9), the scavenger role of 
taurine reduces the oxidative damage by reducing the modification of LDL 
and increasing the bioavailability of NO(236).  
This mechanism together with improvement in vascular tone may 
contribute to the role of taurine in hypertension management(10, 11, 
237). In a recent double blind, placebo controlled study involving 120 
untreated pre-hypertensive and 58 age-matched controls, 12-weeks 
taurine supplementation, significantly decreased the clinic and 24 hour 
ambulatory blood pressure measurement, and also improved 
endothelium dependent and independent vasodilation(11).  
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Similar mechanisms may also play a role in various in-vitro studies 
involving rats and human haemoglobin, whereby taurine inhibited the 
formation of advanced glycation end products (AGEs), which plays a key 
role in development of diabetes complications(238, 239).  
A recent review suggests that the inhibition of these reactive oxygen 
species (ROS) is regulated by mitochondria function with taurine acting 
as a central role at the level of RNA(240). This lead to the proposal that 
taurine depletion in conditions such as diabetes may contribute to 
mitochondrial dysfunction and restoration of taurine level may normalize 
its function and contribute to inhibition of ROS(9). 
In humans, taurine is metabolized into two exchangeable pools, one 
small rapidly exchanging pool (T1/2 0.1 hours) and a larger slowly 
exchanging pool (T1/2 70 hours). It is rapidly excreted, predominantly in 
the urine, 70% as taurine and 25% as sulphate(241). Brons et al 
measured serum taurine in a randomized crossover study in obese non-
diabetic participants, and concluded that 2 weeks washout after each 
treatment with supplemental taurine or placebo was adequate(242). 
Moloney et al also have used similar washout period in a crossover study 
comparing taurine and placebo in patients with T1DM(16).  
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1.4.2 Taurine, Diabetes and Endothelial Dysfunction 
1.4.2.1 Taurine and Animal Models of Diabetes Studies 
Initial animal diabetes studies demonstrated benefits of Taurine in 
suppression of hyperglycaemia, prolonging survival, improving pancreatic 
cell mass, and improving insulin resistance(9).        
In a Streptozocin (STZ)-induced diabetes rats, Taurine supplementation 
through its antioxidant property demonstrated glycaemic improvement, 
lowers glycated haemoglobin (HbA1c) and prolongs survival after 6 
months therapy, compared to diabetes rats without treatment(243, 244).  
In a separate study involving pregnant obese non-diabetic (NOD) mice, 
Taurine supplementation throughout the gestation, demonstrated greater 
pancreatic cell mass, reduced rates of insulinitis and delayed the mean 
onset time for the development of diabetes in the offspring compared to 
placebo(245).  
Similar benefits were also seen in non-insulin dependent obese mice 
(The Otsuka Long-Evans Tokushima Fatty, OLETF) where Taurine 
improved hyperglycaemia, insulin resistance, and suppressed serum 
triglycerides and cholesterol(246, 247).  
In metabolic syndrome induced high fructose fed (HFD) mice, Taurine 
supplementation improved insulin resistance, glucose tolerance, 
hypercholesterolaemia, hypertriglyceridaemia, total antioxidant capacity, 
and nitric oxide metabolites by 11 to 56%, suggestive of a protective 
effect(248). 
In similar animal models, Taurine supplementation has been shown to 
reduce diabetes related complications(9). These include AGE related 
renal injury and fibrosis (249-251), and diabetes retinopathy(252, 253). 
Taurine supplementation also reduced oxidation damage in lens and 
nerves of diabetic animals with potential benefit in preventing cataracts 
and improvement in neuropathy symptoms(9, 254). 
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The benefits of Taurine in modulating endothelial dysfunction in diabetes 
were highlighted in various animal studies. In the Streptozocin induced 
Type 1 diabetes mouse model, Taurine, through its antioxidant property, 
has been shown to improve endothelial dysfunction by downregulating 
LOX-1, an endothelial receptor for ox-LDL, and intracellular adhesion 
molecule-1 (ICAM-1) expression on aortic vascular endothelium(15). 
Acute hyperglycaemia seen in diabetes has been shown to activate 
leucocyte adhesion and migration to endothelium, increased ICAM-1 
production and apoptosis of endothelial cells. Rats given 
supplementations of Taurine prior to exposure to hyperglycaemia had 
reduced leucocytes action, reduced ICAM-1 production and reduced 
endothelial cell apoptosis, suggestive of a role for Taurine in protecting 
against negative consequences of hyperglycaemia(14). 
1.4.2.2 Taurine and Diabetes Human Studies 
There have been numerous human studies involving supplementation 
with Taurine in patients with diabetes(9, 16, 255-258). Plasma and 
platelet taurine levels are lower in participants with type 1 (T1DM) and 
type 2 diabetes (T2DM) compared to normal subjects(255-257). There’s 
also an inverse correlation between log plasma taurine and glycated 
haemoglobin (HbA1c) in similar participants(255).  
A clinical benefit of taurine in T1DM is still debatable(9). Supplementation 
of taurine (0.5 g twice daily) in 10 T1DM participants improved 
carbohydrate metabolism and decreased triglycerides level(259). In 
contrast, the secondary finding of a study where taurine (1.5g per day) 
was supplemented in 39 T1DM participants for 90 day abolishes the 
inverse correlation between log plasma taurine and HbA1c suggestive of 
no significant effect on glycaemic control. The latter study did show 
reduction in platelet aggregation and restoration of taurine level similar to 
control subjects (255).  
Taurine supplementation (3g per day) for 4 months in T2DM participants 
(n=32) did increase plasma taurine level but did not have any significant 
effect on HbA1c level compared to placebo group(258). In a crossover 
 66 
study involving overweight, non-diabetic men (n=20), taurine 
supplementation  (1.5g for 8 weeks) had no effect on insulin secretion, 
insulin sensitivity or on plasma lipid level, suggesting no role of taurine in 
T2DM prevention in a high-risk group(242).  
These studies concluded that taurine supplementation in T2DM does not 
have any significant effect on glycaemic control, in contrast to prior 
animal studies(9).  
The main limitation to these conclusions is that taurine dose per body 
weight in animal studies was more than 10 times higher than in human 
clinical trials. Other limitations include the difference in severity of disease 
among participants, concomitant use of other medications in human 
studies and the duration of trials(9).  
A crossover clinical study by Xiao et al however, demonstrated 
usefulness of taurine against the impairment of insulin sensitivity due to 
increase fatty acids in obese non-diabetic men. By using intravenous 
infusion of Intralipid, a state of induced insulin resistance was created. 
Compared to N-acetylcysteine (NAC), 2 weeks pretreatment with taurine 
ameliorated lipid-induced functional beta cell decompensation and insulin 
resistance, possibly by reducing oxidative stress(260).  
Nakamura et al investigated taurine supplementation (3g/day) on T2DM 
participants with microalbuminuria for 12 months. Similar to the animal 
study, taurine supplementation did not show any benefit in improving 
microalbuminuria and biomarkers of fibrosis such as serum collagen IV 
and plasma matrix metalloproteinase-9 (261) . 
More recently, several studies investigated the role of taurine in 
endothelial dysfunction. Moloney et al investigated the role of taurine in 
reversing the endothelial dysfunction in participants with T1DM. Earlier 
studies by the same group demonstrated reversal of endothelial 
dysfunction assessed by flow-mediated dilatation (FMD), in diabetics with 
pravastatin (262) and in young asymptomatic smokers supplemented with 
taurine(263). In the latter study, they also demonstrated an up-regulation 
 67 
of nitric oxide from monocyte-endothelial cell interaction in subjects who 
received taurine.  
In their recent crossover study, 9 T1DM participants were randomized to 
either taurine (1.5g/day) or placebo for 2 weeks each, with assessment of 
endothelial function using FMD. Control subjects (n=10) underwent a 
baseline scan only. T1DM participants had significant abnormalities in the 
measurement of augmentation index and brachial artery reactivity (FMD) 
indicating early endothelial dysfunction. Both parameters improved after 2 
weeks supplementation with taurine suggestive of a potential benefit in 
preventing progression towards atherosclerosis in this group(16).   
1.4.3 Summary 
Taurine acts as an antioxidant with proven roles in preventing diabetes 
and its complications in animal models through various pathways. The 
benefit in improving glycaemic control in human participants with diabetes 
is unproven, largely due to different doses used compared to animal 
study, small sample sizes, concomitant medications, and short duration of 
study. More recent data suggest a potential role of Taurine in reversing 
endothelial dysfunction that may benefit patients with diabetes. 
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2 Study 1: Cardiovascular safety of DPP-4 inhibition in 
participants with Type 2 Diabetes Mellitus: Endothelial 
Progenitor Cells as an early marker of long-term cardiovascular 
risk 
2.1 Introduction 
Diabetes mellitus is defined as a metabolic disorder of multiple aetiology 
characterized by chronic hyperglycaemia with disturbance of 
carbohydrate, fat, and protein metabolism resulting from defect in insulin 
secretion, insulin action or both (89). T2DM is characterized by 
progressive insulin secretory defect on background of insulin resistance. 
It is a complex chronic illness requiring continuous medical care with 
multifactorial risk reduction strategies beyond glycaemic control (90). 
Today, macrovascular complications (CVD including stroke) are the most 
common cause of death in participants with diabetes compared to 
microvascular complications (retinopathy, nephropathy)(90). When 
diabetes patients develop CVD, they have worse prognosis compared to 
patients without diabetes(97, 98) and are more likely to develop 
cardiomyopathy in the future(99, 100). 
Endothelial Progenitor Cells (EPCs) are defined as circulating bone 
marrow derived cells capable of postnatal vasculogenesis and vascular 
homeostasis (17). Numerous studies have confirmed, both directly and 
indirectly, the central role of EPCs in cardiovascular repair processes. 
The accumulated evidences suggests that a balance between the 
damaging effects of conventional cardiovascular risk factors and the 
ability of circulating EPCs to effect endothelial repair determines 
cardiovascular risk(1, 7, 78, 264, 265). EPC numbers in patients with 
Type 2 Diabetes (T2DM) have been shown to be significantly lower than 
in non-diabetics, and recent study have shown an increase in EPC 
numbers with intensive treatment of T2DM(86).  
The controversy regarding the potential harmful cardiovascular effects of 
Rosiglitazone(144) has resulted in an increased awareness of the need to 
more closely evaluate the potential CV benefits and risks of new 
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antihyperglycaemic agents(150). Unfortunately, long-term post-marketing 
trials are often required before an adverse cardiovascular signal can be 
detected.  
Dipeptidyl Peptidase-4 inhibitors (DPP4i) are a new class of treatment for 
T2DM, which are licensed for use as monotherapy or dual therapy with 
metformin and/or a sulphonylurea when glycaemic targets are not 
achieved. DPP-4 degrades glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP); two incretin hormones that have 
been shown to be important in glucose and appetite regulation. Inhibiting 
DPP-4 enhances the effect of GLP-1 and GIP, resulting in an increase in 
glucose-dependent insulin secretion and suppressing post-prandial 
glucagon secretion. While DPP-4 inhibitors are effective glucose-lowering 
agents, at the initiation of this study, there were no published data on its 
cardiovascular safety (155) or benefit.  
In a 4 week non-randomized, non-blinded study of EPCs in patients with 
T2DM, Sitagliptin, a DPP-4 inhibitor was found to elevate the number of 
EPCs (as determined by flow cytometry) compared to patients prescribed 
no additional oral anti-diabetic agent(184). 
We propose to conduct a long-term open-labeled randomized trial 
examining the effects of DPP-4 inhibitor (Saxagliptin) versus 
sulphonylurea therapy on EPC numbers and function in patients with 
T2DM, in an attempt to find an early marker of potential cardiovascular 
risk or benefit of these medications in patients with T2DM.  
2.2 Methods 
Diabetes patients on maximum doses of metformin therapy who require 
addition of another oral anti-diabetic agent based on clinical need, and in 
whom the benefits and risks of sulphonylurea (SU) therapy versus DPP-4 
inhibitor therapy are felt not to favour one agent over the other, were 
recruited and randomized to receive either DPP-4 inhibitor (Saxagliptin, 
SAX) or SU (Gliclazide Modified Release, GLC) treatment. 
 70 
Participants were identified when they attended the routine visits at the 
diabetes outpatient clinic and the diabetes day centre at Connolly 
Hospital from March 2011 to October 2012. The study was discussed and 
a patient information leaflet was given (Appendix section 4.1.1). 
Participants who agreed to the study were given an appointment to attend 
the diabetes day centre, where fully informed consent (Appendix section 
4.1.2) was obtained.  
The following inclusion criteria includes having T2DM, HbA1c > 7.0% 
(53mmol/mol), and on treatment with metformin 850 mg twice a day or 
more. Participants who were pregnant, on oral contraceptive pill, 
breastfeeding, had HbA1c> 10% (86mmol/mol), documented renal 
impairment (cc <60 mL/min) and/or hepatic impairment, alcoholism, had 
inter-current illness, foot ulcer, significant retinopathy, active infection, 
previous myocardial infarction, heart failure, stroke, and documented 
peripheral vascular disease or absent peripheral pulses were excluded 
from the study. 
All participants signed an informed consent and this study was approved 
by the Connolly Hospital Ethics Committee. 
On the first visit, participants had anthropological measurements (weight, 
body mass index, waist circumference, waist to hip ratio), clinical 
assessment (medical history, medications, blood pressure), routine blood 
testing (renal/ liver/ bone profile, HbA1c) and additional blood sampling for 
EPC culture. Height and weight were measured without shoes and 
rounded to the closest 0.5cm and nearest kg. Waist circumference was 
measured using non-stretchable tape, while standing, feet together, 
midpoint between lower rib margin and iliac crest.  
By using a random number generator, each participant was randomly 
assigned either Saxagliptin 5mg daily or Gliclazide MR 30mg daily as a 
second line anti-diabetic treatment.  Participants were contacted monthly 
in order to monitor any potential side effects. Participants in the Gliclazide 
group had their doses titrated to a maximum of 120mg daily based on 
blood glucose diary review. Dose of Gliclazide was reduced if there was 
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any evidence of hypoglycaemia. Participants on Saxagliptin remained on 
the same dose throughout the study.  
Anthropometric measurements, clinical assessment, blood testing and 
EPC culture were repeated at 6 months review. At that time, participant’s 
overall diabetic control was reviewed and further treatment 
recommendations were planned as per the current treatment guidelines.  
2.2.1 EPC Isolation and Adhesion Assay 
2.2.1.1 EPC Isolation 
The technique for EPC isolation was similar to previous studies in our 
group(4, 39, 266). 60 mls of peripheral blood was decanted into 3 x 20mls 
of Hanks Balanced Salt Solution (HBSS). This mixture was layered onto 4 
x 15 mls of Ficoll-Paque giving to a total of 45mls for each bottle. 
Each sample was centrifuged at 1800 rpm at 30 minutes with 
acceleration of 3 and deceleration of 0. By using a Pasteur pipette, the 
mononuclear cell layer was separated from each bottle into another 
50mls bottle. 
The removed mononuclear layer was centrifuged at 1600 rpm for 10 
minutes with acceleration of 3 and deceleration of 0. 5mls of Red Cell 
Lysis buffer was added to the pellet, which then undergoes another 
centrifugation at 1600 rpm for 10 minutes at acceleration and 
deceleration of 9.  
This process was repeated twice, with further pellet washing using 
Phosphate Buffer Saline (PBS) before suspending the pellet in 
Endothelial Growth Media 2 (EGM-2) solution.  
Using a haemocytometer, the volume of cells corresponding to 10x 106 
were calculated. This volume constitutes the amount of cells to be plated 
into each well of fibronectin coated 6-well plates. The desired volume of 
cells was added onto the corresponding volume of EGM-2 to give a total 
volume of 2000µl for each well of the 6-well plate.  
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The plate was labeled and incubated in a 370c with 5% of CO2 incubator 
for 7 days. On day 4, the non-adherent cells were removed and the 
media was replaced. 
2.2.2 Identification of EPC 
On day 7, after washing the well, 10µl of acetylated low-density DiL-
labelled LDL (DiL-AcLDL) were added followed by 1ml of media (Figure 
2-1).  
After 4 hours incubation, cells were washed and media was replaced. By 
using fluorescent microscope and red filter, cells incorporating DiL-AcLDL 
fluorescence red were identified as potential circulating EPCs (Figure 2-
2).  
20mcl of Ulex Lectin were added to the well. After 3 hours of incubation, 
cells were washed and media was replaced. Using the fluorescent 
microscope and green filter, cells expressing Lectin, with fluorescence 
green was identified as potential EPCs (Figure 2-3).  
 
 
Figure 2-1: Dual staining of Endothelial Progenitor Cells (EPCs) at day 7 
under light microscopy (400x magnification). 
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Figure 2-2 Dual staining of EPCs. Incorporation of acetylated low-density 
DiL-labelled LDL (DiL-AcLDL) (red colour) under fluorescence 
microscope with red filter 
 
Figure 2-3: Dual staining of EPCs. Incorporation of Ulex Lectin (green 
colour) under fluorescence microscope with green filter 
 
2.2.3 Counting EPC 
On day 7, the 6-well plates are washed twice to remove any non-
adherent cells. Adherent cells in 12 random microscope fields (4 in each 
randomly chosen well) were photographed at 400x magnification before 
another period of incubation for 15 minutes. Cells in the photographed 
were counted by a single investigator and was validated by an 
independent investigator. 
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After 15 minutes, Enzyme Free Cell Dissociation Buffer was added to 
each well followed by 30 minutes of incubation. Detached cells underwent 
centrifugation at 1500 rpm for 10 minutes. 
Pellet was suspended in Serum Free Media (SFM) and using a 
haemocytometer, the volume of cells corresponding to 5 x 104 cells were 
calculated.  
2.2.4 Adhesion Assay 
Using a 96-well plate, Human Fibronectin 0.1% and HBSS were added to 
wells A1 to A5 and control wells (H1 to H5). After an overnight incubation, 
these wells were blocked using Bovine Serum Albumin (BSA) and 
incubated for 2 hours.  
After 2 hours, each well was washed using PBS. 
Detached day 7 cells (5 x 104) were plated onto wells A1 to A5. A similar 
volume of SFM without cells was added onto control wells before they 
were incubated for 1 hour.  
After 1 hour, wells were washed with PBS and cells were fixed with 
formaldehyde. 
Crystal violet was added to each well and after rinsing with PBS, plates 
were allowed to dry for 30 minutes. 
The centre of each well with cells was photographed (Figure 2-4). 
Methanol was added to wells to elute the stains from the cells before 
undergoing analysis in the plate reader at 595nm wavelength for 0.1sec. 
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Figure 2-4: EPC Adhesion assay. Isolated EPC stained with crystal violet 
(purple colour) adhering to fibronectin coated well on Day 7.   
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2.3 Statistical analysis 
Data were analyzed based on treatment group. Categorical data were 
compared using chi-square test. Continuous data were tested for 
normality. Normally distributed data were expressed using mean ± SD 
and non-normally distributed data were expressed in median (IQ range). 
Independent sample T-test was used in normally distributed data while 
Mann-Whitney test was used in non-normally distributed data when 
comparing between treatment groups. Eta squared was used to calculate 
the magnitude of the differences in means between treatment groups. 
Spearman correlation was used to correlate parameters at baseline. 
Paired T-test and Wilcoxon Signed Rank Test was used to compare data 
at baseline and at 6 months follow up based on randomization. Significant 
p value of < 0.05 is considered significant in all data analyses.  
2.4 Results 
A total of 18 participants with T2DM on metformin monotherapy requiring 
diabetes intensification were identified, 12 were males and 6 were 
females.  
Baseline age, body mass index (BMI), waist hip ratio (WHR), systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) are illustrated in 
Table 2-1. Mean diabetes duration was 4 years with a baseline glycated 
haemoglobin (HbA1c) of 58.7 ± 8.6 mmol/mol. Baseline creatinine and 
spot urine albumin creatinine ration (ACR) were 73.3 ± 19.2 mmol/L and 
0.85 (0.55 – 2.7) mg/mmol respectively. Baseline total cholesterol (TC), 
HDL cholesterol (HDL), LDL cholesterol (LDL) and Triglycerides (TG) 
were 4.2 ±1.1, 1.1 (1.1 – 1.3), 2.2 ± 0.8 and 1.8 ± 1.1mmol/L respectively. 
Baseline EPC count was 30 (21 – 43) cells/hpf while EPC adhesion 
capacity was 0.24 (0.16 – 0.69) fluorescence unit respectively.  
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Table 2-1 Parameters at baseline (Study 1). Normally distributed data are 
expressed as mean ± SD while skewed data are expressed as median 
(interquartile range, IQ range). ACEI (Angiotensin Converting Enzyme 
Inhibitor), ARB (Angiotensin Receptor Blocker), BMI (Body Mass Index), 
HbA1c (Glycated Haemoglobin), ACR (Albumin Creatinine Ratio), HDL 
(High Density Lipoprotein), LDL (Low Density Lipoprotein), EPC 
(Endothelial Progenitor Cells) 
Baseline Characteristics Values 
Total patients 18 
Age (years) 56.5 ± 7.6 
Diabetes Duration (years) 4.11 ± 2.3 
Gender (n, %) 
Male 
Female 
 
12 (66.7) 
6 (33.3) 
BMI (kg/m2) 30.2 ± 2.9 
Waist Hip Ratio (WHR) 0.96 ± 0.07 
Systolic Blood Pressure (mmHg) 141.7 ± 22.7 
Diastolic Blood Pressure (mmHg) 85.7 ± 12.1 
Concomitant Medications (n, %) 
Statin 
Aspirin 
ACEI 
ARB 
Metformin 
 
16 (88.9) 
17 (94.4) 
5 (27.8) 
4 (22.2) 
18 (100) 
Smoker (n, %) 3 (16.7) 
Fasting Glucose (mmol/L) 8.3 ± 1.5 
HbA1c (mmol/mol) 58.7 ± 8.6 
Creatinine (mmol/L) 73.3 ± 19.2 
Urine ACR (mg/mmol) 0.85 (0.55 – 2.7) 
Total Cholesterol (mmol/L) 4.2 ± 1.1 
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Baseline Characteristics Values 
HDL Cholesterol (mmol/L) 1.2 (1.1 – 1.3) 
LDL Cholesterol (mmol/L) 2.2 ± 0.8 
Triglycerides (mmol/L) 1.8 ± 1.1 
EPC per high power field (EPC/hpf, 
cells) 
30 (21 – 43) 
EPC adhesion (fluorescence unit) 0.24 (0.16 – 0.69) 
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Correlation analysis was performed to identify any association between 
EPC and parameters at baseline. There were positive correlations 
between diabetes duration and the numbers of EPC per high power field 
(EPC/hpf, rho = 0.522, p=0.032) and EPC adhesion capacity (EPC 
adhesion, rho 0.518, p=0.028) (Figure 2-5 and 2-6). Baseline diastolic 
blood pressure (DBP) however had an inverse relationship to EPC 
adhesion (rho= -0.52, p=0.026) (Figure 2-7). There were no significant 
correlations between baseline EPC/hpf or EPC adhesion to age, gender, 
smoking status, concomitant treatment [statin, Angiotensin Receptor 
Blocker (ARB), Angiotensin Converting Enzyme Inhibitor (ACEI), and 
aspirin], WHR), glycaemic control and lipid levels.  
 
 
Figure 2-5 Spearman correlation between diabetes duration and EPC 
numbers at baseline (Study 1). There was a positive relationship between 
the numbers of EPC per high power field (EPC/hpf, cell) and diabetes 
duration (years) at baseline.  
 
 
 
 
rho 0.522, p=0.032 
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Figure 2-6 Spearman correlation between diabetes duration and EPC 
adhesion at baseline (Study 1). There was a positive relationship 
between EPC Adhesion (fluorescence unit) and diabetes duration (years) 
at baseline. 
 
Figure 2-7 Spearman correlation between baseline DBP and EPC 
adhesion (Study 1). There was a negative relationship between EPC 
Adhesion (fluorescence unit) and diastolic blood pressure (DBP, mmHg) 
at baseline. 
 
rho -0.523, p=0.026 
rho 0.518, p=0.028 
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Participants were randomized to either SAX (n=7) or GLC (n=11) as part 
of their treatment intensification. Due to technical reasons, one participant 
did not have adequate EPC cells counted at baseline while another 
participant did not have adequate EPC cell culture at 6 months review.  
There were no significant differences of age, gender, smoking status, 
BMI, WHR, SBP, DBP, diabetes duration, and glucose at baseline 
between treatment groups (Table 2-2). There were no significant 
differences in the concomitant use of statin, ARB, ACEI or aspirin 
between treatment groups. There were no significant differences in the 
number of total EPC/hpf with median (IQ range) of 33 (19 – 44) cells in 
SAX group (n=6) and 25 (22 – 46) cells in the GLC group (n=11, p=0.9). 
Similarly, there were no differences in the adhesion capacity of EPC 
between both groups with median (IQ range) of 0.22 (0.17 – 0.86) 
fluorescence units in the SAX group (n=7) compared to 0.27 (0.1 – 0.67) 
fluorescence units in the GLC group (n=11, p=0.75).  
At baseline, HbA1c was higher in the GLC group compared to SAX group 
(62.3 ± 8.8 vs. 53.1 ± 4.4mmol/mol, p=0.02) while creatinine level was 
higher in SAX group compared to GLC group (88.9 ±15.2 vs 63.5 ± 14.5 
mmol/L, p=0.003). The magnitude of the differences between the means 
of HbA1c and creatinine were large with an eta squared of 0.44 for HbA1c 
and 0.29 for creatinine respectively.  
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Table 2-2 Comparison between baseline parameters based on treatment (Study 
1). HbA1c and Creatinine levels were different at baseline. Normally distributed 
data are expressed as mean ± SD while skewed data are expressed as median 
(interquartile range, IQ range). BMI (Body Mass Index), WHR (Waist Hip Ratio), 
SBP (Systolic Blood Pressure), DBP (Diastolic Blood Pressure), HbA1C 
(Glycated Haemoglobin), ARB (Angiotensin Receptor Blocker), ACEI 
(Angiotensin Converting Enzyme Inhibitor), ACR (Albumin Creatinine Ratio). 
HDL (High Density Lipoprotein), LDL (Low Density Lipoprotein), EPC 
(Endothelial Progenitor Cells). Significant differences considered at p< 0.05. 
Baseline Parameters Saxagliptin (n=7) DMR (n=11) Sig 
Gender n (%) 
Female 
Male 
 
1(14.3) 
6(85.7) 
 
5(45.5) 
6(54.5) 
 
0.39 
Smoker n (%) 0 3(27.3) 0.39 
Age (mean ± SD, 
years) 
57.9 ± 6.1 55.5 ± 8.6 0.54 
BMI (mean ± SD, 
kg/m2) 
29.4 ± 1.8 30.7 ± 3.4 0.36 
WHR n (mean ± SD) 6(0.94 ±0.33) 11(0.97 ± 0.08) 0.44 
SBP  (mean ± SD, 
mmHg) 
145.1 ± 28.1 139.5 ± 19.7 0.62 
DBP (mean ± SD, 
mmHg) 
88.4 ± 14.5 83.9 ± 10.7 0.46 
Diabetes Duration n 
(mean ± SD, years) 
4.9 ± 2.7 3.6 ± 2.0 0.29 
Creatinine (mean ± SD, 
mmol/L) 
88.9 ± 15.2 63.5 ± 14.5 0.003 
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Baseline Parameters Saxagliptin (n=7) DMR (n=11) Sig 
Urine ACR, n [med(IQ 
range), mg/mmol] 
6, 0.85 (0.55 – 
10.38) 
11, 0.85 (0.5 – 2.5) 0.61 
Glucose, n (mean ± 
SD, mmol/L) 
5(7.5 ± 0.7) 7(8.8 ± 1.8) 0.16 
HbA1c (mean ± SD, 
mmol/mol) 
53.1 ± 4.4 62.3 ± 8.8 0.02 
Total Cholesterol 
(mean ± SD, mmol/L) 
3.7 ± 1.0 4.6 ± 1.1 0.09 
HDL Cholesterol 
[med(IQ range), 
mmol/L)] 
1.2 (1.0 – 1.6) 1.2 (1.1 – 1.3) 0.82 
LDL Cholesterol (mean 
± SD, mmol/L) 
1.8 ± 0.7 2.4 ± 0.7 0.12 
Triglycerides (mmol/L) 1.3 ± 0.6 2.0 ± 1.2 0.18 
Medications n (%) 
Statin 
ARB 
ACEI 
Aspirin 
 
6 (85.7) 
3 (42.9) 
4 (57.1) 
7 (100) 
 
10 (90.9) 
1 (9.1) 
5 (45.5) 
10 (90.9) 
 
1.0 
0.27 
1.0 
1.0 
Total EPC per HPF, n 
[med(IQ range), 
cells/hpf] 
6 [33 (19 – 44)] 11 [25 (22 – 46)] 0.9 
EPC Adhesion, 
[med(IQ range), 
fluorescence unit] 
7[0.22(0.17 – 0.86)] 10[0.27 (0.1 – 
0.67)] 
0.75 
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In all participants, the addition of a second antihyperglycaemic medication 
improved HbA1c at 6 months compared to baseline (54.9 ± 8.4 vs. 58.9 ± 
8.8 mmol/mol, p=0.06).  
Table 2-3 demonstrates the comparison of all parameters at baseline and 
at 6 months, based on randomized intervention. In the GLC group, there 
was a downward trend of HbA1c from 62.3 ± 8.8 to 57.1 ± 8.5 mmol/mol 
(p=0.08) and from 53.1 ± 4.4 to 50.4 ± 6.6mmol/mol (p=0.33) in the SAX 
group. Fasting glucose were significantly lower in GLC group (9.1 ± 1.8 to 
7.9 ± 1.8 mmol/L, p=0.02) while no difference seen in SAX group (7.4 ± 
0.7 to 7.2 ± 1.4 mmol/L, p=0.73) (Table 2-3, Figure 2-8). Weight was 
significantly increased in the GLC group at 6 months (85.96 ± 14.68 to 
87.89 ±14.93 kg, p=0.008) while no change was seen in SAX group 
(84.23 ± 9.9 to 84.51 ± 9.55 kg, p=0.75). This contributed to the 
increased of BMI in GLC group (30.7 ± 3.4 to 31.4 ± 3.4 kg/m2, p=0.02) 
compared to SAX group (29.4 ± 1.8 to 29.2 ± 2.0 kg/m2, p=0.72) (Table 2-
3, Figure 2-9). There were no significant changes in SBP, DBP, 
cholesterol profile, and urine ACR in each group, during follow up. All 
smokers (n=3 in the GLC group) reported continuing smoking during the 
study.  
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Table 2-3: Comparison between changes in parameters with treatment (Study 
1). BMI and fasting glucose were different at follow up in GLC group. BMI (Body 
Mass Index), WHR (Waist Hip Ratio), SBP (Systolic Blood Pressure), DBP 
(Diastolic Blood Pressure), HbA1C (Glycated Haemoglobin), ARB (Angiotensin 
Receptor Blocker), ACEI (Angiotensin Converting Enzyme Inhibitor), ACR 
(Albumin Creatinine Ratio), SAX (Saxagliptin), GLC (Gliclazide MR), HDL (High 
Density Lipoprotein), LDL (Low Density Lipoprotein), EPC (Endothelial 
Progenitor Cells). Significant value p< 0.05. 
Parameters Intervention Baseline 6 months Sig 
BMI, n (mean ± SD, 
kg/m2) 
SAX 7(29.4 ± 
1.8) 
7(29.2 ± 
2.0) 
0.72 
GLC 11(30.7 ± 
3.4) 
11(31.4 ± 
3.4) 
0.02 
WHR, n (mean ± 
SD) 
SAX 6(0.94 ± 
0.03) 
6(0.93 ± 
0.03) 
0.24 
GLC 11(0.97 ± 
0.08) 
11(0.95 ± 
0.08) 
 
0.33 
SBP, n (mean ± 
SD, mmHg)  
SAX 7(145.1 ± 
28.1) 
7(146.1 ± 
19.4) 
0.82 
GLC 11(139.5 ± 
19.7) 
11(138.5 ± 
23.4) 
0.87 
DBP, n (mean ± 
SD, mmHg) 
SAX 7(88.4 ± 
14.5) 
7(89 ± 7.9) 0.85 
GLC 11(83.9 ± 
10.7) 
11(81.5 ± 
11.1) 
0.35 
Creatinine, n (mean 
± SD, mmol/L)  
SAX 7(88.9 ± 
15.2) 
7(87 ± 13.7) 0.16 
GLC 11(63.5 ± 
14.5) 
11(66.1 ± 
15.5) 
0.23 
Glucose, n (mean ± 
SD, mmol/L)  
SAX 4(7.4 ± 0.7) 4(7.2 ± 1.4) 0.73 
GLC 6(9.1 ± 1.8) 6(7.9 ± 1.8) 0.02 
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Parameters Intervention Baseline 6 months Sig 
HbA1c, n (mean ± 
SD, mmol/mol) 
SAX 7(53.1 ± 
4.4) 
7(50.4 ± 
6.6) 
0.33 
GLC 11(62.3 ± 
8.8) 
11(57.1 ± 
8.5 
0.08 
Urine ACR, n 
[med(IQ range), 
mg/mmol] 
SAX 6[0.85 
(0.55 – 
10.4)] 
7[1.0(0.5 – 
10.5)] 
0.67 
GLC 11[0.85(0.5 
– 2.5) 
10[0.7(0.48 
– 1.48)] 
0.8 
Total Cholesterol, n 
(mmol/L) 
SAX 7(3.7 ± 1.0) 7(3.7 ± 0.7) 0.92 
GLC 11(4.6 ± 
1.1) 
11(4.5 ± 
1.3) 
0.6 
HDL Cholesterol, n 
[med(IQ range), 
mmol/L)] 
SAX 7[1.2(1.0 -
1.6)] 
7[1.4(1.1 – 
1.7)] 
0.55 
GLC 11[1.2(1.1 
– 1.3)] 
 
11[1.2(1.1 – 
1.3)] 
0.76 
LDL Cholesterol, n 
(mmol/L) 
SAX 7(1.8 ± 0.7) 7(1.6 ± 0.5) 0.24 
GLC 10(2.4 ± 
0.8) 
10(2.3 ±1.0) 0.93 
Triglycerides, n 
(mmol/L) 
SAX 7(1.3 ± 0.6) 7(1.3 ± 0.5) 0.7 
GLC 11(2.0 ± 
1.2) 
11(2.0 ± 
1.3) 
0.77 
Total EPC/hpf, n 
[med(IQ range), 
cells/hpf] 
SAX 6[33(19 – 
44)] 
7[35(28 – 
38)] 
0.92 
GLC 11[25(22-
46)] 
10[39(28 – 
46)] 
0.24 
EPC Adhesion, n 
[med(IQ range), 
fluorescence unit] 
SAX 7[0.22(0.17 
– 0.86) 
7[0.3(0.17 – 
0.65)] 
1.0 
GLC 11[0.27(0.1 
– 0.67)] 
10[0.32(0.14 
– 0.84)] 
0.88 
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Figure 2-8 Changes in mean fasting glucose (mmol/L) at 6 months compared to 
baseline according to treatment (Study 1). Fasting glucose was lower in 
Gliclazide MR (GLC) group while no changes seen in Saxagliptin group. Error 
bar represents confidence interval at 95%. NS (Non significant). Significant 
difference at p<0.05.  
 
Figure 2-9 Changes in mean BMI (kg/m2) at 6 months compared to baseline 
according to treatment (Study 1). BMI was higher in Gliclazide MR (GLC) group 
while no changes seen in Saxagliptin group. Error bar represents confidence 
interval at 95%. NS (Non significant). Significant difference at p<0.05. 
p=0.02 NS 
p=0.02 NS 
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In the SAX group, there were no significant changes in EPC numbers per 
high power field at 6 months compared to baseline [n=7, 35 (28 – 38) 
from n=6, 33 (19 – 44) cells/hpf, p=0.9] (Figure 2-10). Similarly, there 
were no significant changes in EPC adhesion capacity at 6 months 
compared to baseline [n=7, 0.3 (0.17 – 0.65) from n=7, 0.22 (0.17 – 0.86) 
fluorescence units, p=1.0] (Figure 2-11). 
In the GLC group, no significant changes were demonstrated in the EPC 
numbers per high power field at 6 months [n=10, 39 (28 – 46) from n=11, 
25 (22 – 46) cells/hpf, p=0.24] (Figure 2-10) and EPC adhesion capacity 
[n=10, 0.32 (0.14 – 0.84) from n=11, 0.27 (0.1 – 0.67) fluorescence units, 
p=0.88] compared to baseline (Figure 2-11).  
 
 
Figure 2-10 Changes in median EPC numbers per high power fields (hpf) 
at 6 months compared to baseline according to treatment (Study 1). No 
difference between EPC/hpf at 6 months in both groups compared to 
baseline. NS (Non significant) 
NS NS 
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Figure 2-11: Changes in median EPC adhesion at 6 months compared to 
baseline according to treatment (Study 1). No difference between EPC 
adhesion (fluorescence unit) at 6 months in both groups compared to 
baseline. NS (Non significant). 
 
 
  
NS NS 
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2.5 Discussion 
We demonstrated no significant difference in EPC numbers and adhesion 
capacity in participants with T2DM treated for 6 months with either 
Saxagliptin or Gliclazide MR in addition to Metformin therapy. The result 
may be interpreted as an absence of early adverse vascular changes 
when Saxagliptin is added to Metformin therapy, and a potential neutral 
CV outcome profile, compared to Gliclazide MR, a well-established 
glucose-lowering medication, in participants with T2DM.  
EPC is a surrogate biological marker for vascular function and cumulative 
vascular risk. It has an inverse correlation with the traditional CV risk 
assessment such as Framingham score and cholesterol level with a 
positive correlation with flow mediated dilatation (FMD)(7); a well 
validated measurement of arterial stiffness(196). EPC changes early in 
vascular disease and have been shown to predict atherosclerosis 
progression, as demonstrated in a 10-year prospective study involving 
healthy controls and participants with coronary artery disease and acute 
coronary syndrome(78). When our study was performed, there was no 
published long-term CV safety data on DPP4i especially Saxagliptin. As a 
surrogate marker of future CVD, any changes in EPC while on this 
treatment may influence treatment decision for patients who require 
intensification of therapy.  
We choose a Sulphonylurea (SU) as our comparator as it is widely used, 
and are considered safe. Gliclazide have been shown to have a free 
radical scavenging activity due to its unique aminoazabicyclo-octane ring 
resulting in an improvement in EPC numbers in patients with T2DM better 
than metformin monotherapy alone(187).  This may contribute the slight 
improvement seen in EPC in the GLC group in our study, although not 
reaching statistical significance.  
2.5.1 Comparison to other published studies 
Studies in T2DM patients, evaluating the effects of DPP4 inhibitors on 
EPC numbers and functions have been performed by Poncina (185) and 
Fadini et al(184) using Saxagliptin and Sitagliptin respectively. Both of 
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these studies used different methodology compared to ours. However, 
their findings can provided some insight to our results.  
In the study by Fadini et al, the addition of Sitagliptin for 4 weeks 
improved the level of EPC by 2 fold and plasma SDF1-α by 50%, in 
T2DM patients already treated with metformin and/or secretagogues 
when compared to no treatment(184).  
Compared to our study, participants in this study were older and had 
higher CV risk with preexisting micro and macrovascular complications. 
Subjects had shorter follow up period of 4 weeks and control patients 
were not assigned to any additional treatment during follow-up.  
EPCs were measured using flow cytometry and without any additional 
cell functional study. In our study, by assigning each participant with 
either Gliclazide MR or Saxagliptin for a longer period of 6 months, we 
were able to compare the newer class of antidiabetic medication to a 
well-recognized treatment with a proven CV safety profile. By performing 
EPC culture and adhesion study, we were able to compare not only the 
changes in numbers but also the function of EPCs, and characterize any 
potential CV benefit or harm.  
Our study methodology and patient selection criteria are more clinically 
relevant in terms of helping clinicians to decide in a real world setting the 
benefit/risk of new antidiabetic medications for patients who needed 
optimization of their diabetes control.  
The increasingly important role of SDF1-α was highlighted by Poncina et 
al. Saxagliptin at an equivalent dose of 5mg and/or SDF1-α was added to 
the cell culture of pro-angiogenic cells (PACs) including EPC, derived 
from patients with T2DM(185).  
In parallel with our results, in this study, Saxagliptin and/or SDF1-α did 
not restore the formation of PACs colony and had no effect on the 
percentage of cells with dual-staining acLDL+Lectin+, which are cells of 
interest to us.  
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Saxagliptin in the presence of SDF1-α however, increased PACs cell 
adhesion in T2DM patients while it has no effect on PACs from healthy 
volunteers. T2DM patients had lower genes expressions responsible for 
regulating cell cycles, apoptosis, and adhesions. Additionally, there was 
higher expression of DPP4 gene, which further reduces the availability of 
SDF1-α.  
As we did not measure the level of SDF1-α in our study, we can only 
postulate that the level would be similarly attenuated in our cohort. The 
inability of Saxagliptin to modify this gene expression may explain the 
absent of effect seen in our study.  
Similar to the study by Fadini et al, subjects were older in the Poncina 
study and had higher rates of vascular complications at baseline 
compared to our cohort. Saxagliptin was added to the in-vitro assay 
rather than as part of the treatment for diabetes. Only 1/3 of the PACs 
cells in this study double stained positive for acetylated LDL and Ulex-
lectin (acLDL+ Lectin+) and the heterogeneous nature of PACs cultures 
may potentially be a limiting factor into the interpretation of the findings 
(185). For EPC adhesion study, we used matrix molecule fibronectin 
instead of HUVEC as a medium for adhesion and this has been reliably 
validated as a suitable medium for EPC adhesions(2, 4). 
2.5.2 Discussion of Literature in Relation to Study Results 
We identified a positive correlation between the numbers of EPCs and 
EPC adhesion capacity and the duration of diabetes at baseline in our 
cohort. We also demonstrated a negative correlation between DBP and 
EPC adhesion at baseline. The mean diabetes duration at baseline in our 
participants was 4.11 ± 2.3 years. A previous cross sectional study of 425 
subjects with normal glucose tolerance, pre-diabetes, and T2DM 
demonstrated 2 nadir points of EPC as measured using flow cytometry. 
Adjusted for any potential confounders, the 1st nadir point happens at 
diagnosis, followed by a maximum partial recovery at ≤ 10 years post 
diagnosis before a second nadir at 20 years post diagnosis of 
diabetes(170). It is possible that the levels of EPCs in our participants 
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were in the recovery phase at the time of participation in our study and 
this may also contribute to the positive effect seen on the DBP. At the 
same time, we could not outrule a potential type-2 error contributing to 
the findings, considering a small sample size.  
HbA1c level was significantly higher in GLC group at baseline compared 
to SAX group. Although the difference was large (as per eta squared), we 
demonstrated no significant correlation between HbA1c level and EPC 
numbers at baseline. Additionally, there are multifactorial factors 
contributing to rise and fall of EPC (38, 85, 87, 267) rather than HbA1c 
alone. In the intervention study by Fadini et al, a negative correlation 
between EPC numbers and fasting glucose were demonstrated at 
baseline. However, the correlation was lost 4 weeks into treatment with 
Sitagliptin, despite improvement of plasma glucose and EPC level(184). 
This supports the notion that many other factors contribute to EPC 
improvement rather than glycaemic improvement alone.  
Due to their higher baseline HbA1c, it is not surprising that participants in 
the GLC group had a statistical significant improvement in fasting glucose 
and demonstrated a trend of improvement in HbA1c compared to the SAX 
group. Due to the difference in mode of action, we were not surprised to 
find that BMI was significantly elevated in GLC group while SAX group 
demonstrated no weight changes (weight neutral). This, together with the 
clinical improvement in HbA1c, suggests that our participants were 
treated adequately and at least were compliant with their treatment.  
Our results parallel the most recent Saxagliptin CV outcome study, the 
SAVOR-TIMI 53, which demonstrated no increased risk of primary or 
secondary CV composite end-points including in patients with pre-existing 
heart failure(155). Unexpectedly, there was an increase in hospitalization 
for heart failure (CHF) in patients randomized to Saxagliptin compared to 
placebo. The risk was higher in patients with high overall risk of heart 
failure (pre-existing disease, impaired renal function and elevated 
baseline NT-proBNP) and considerably lower in patients with low risk at 
baseline. Considering the study as one of the largest studies involving 
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diabetes patients with pre-existing heart failure (n=2105), the absence of 
pre-clinical data or known mechanisms causing heart failure due to DPP4 
inhibition and the nature of this study with multiple testing, this 
unexpected finding remained unexplained(268).  
The fact that the results of our study are consistent with an outcome of a 
large long-term clinical outcome study, it continue to add to the evidence 
that EPC are useful early markers of long-term CV risk in the evaluation 
of any therapeutic agent.  
2.5.3 Limitations and Strengths 
Our study has a few limitations. Despite our best effort, we managed to 
only recruit 18 participants within 18 months from our diabetes clinic and 
diabetes day centre. With more subjects, we may be able to provide 
additional power to our analysis, minimizing the risk of statistical error. At 
baseline, our participants had a short duration of diabetes, most were on 
multidrug therapy, and potentially therefore had lower risk for CVD 
compared to other studies. As highlighted, this may contribute to a natural 
improvement of EPC beyond glycaemic influence. It is not known if this 
natural recovery at baseline reached a threshold for maximum reduction 
in CV risk. Future study involving comparison of EPC with normal healthy 
control may answer this. However, we felt that the criteria in selecting the 
study population are justified. As Saxagliptin is being used more often as 
a second line agent, in patients relatively early in the diagnosis of 
diabetes, the impact of this finding will affect this cohort more than other 
diabetics with higher CV risk and longer duration.  
We kept our study as close to the real world experience as much as 
possible. Our participants were recruited on the basis of clinical need, in 
whom the benefits and risks of Gliclazide MR versus Saxagliptin were felt 
not to favour one agent over the other. Rather than using to placebo, we 
compared a new class of antidiabetic to a well-known antidiabetic 
medication with proven long-term use without CV complications. 
Participants were treated and followed up as per standard current 
practice. These steps are important in ensuring that our results are more 
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clinically relevant, hoping that we may guide clinicians to tailor their 
treatment to their patient.   
In order to further evaluate the risk/benefit of DPP4i, future studies should 
include more participants with T2DM with healthy controls as a 
comparator. A different cohort with a stable history of CVD or CHF is the 
natural next step.  
2.5.4 Summary 
In summary, EPCs are well-established surrogate markers of CVD in 
general and diabetes population. Establishing CV safety of new 
antidiabetic medication is paramount. Therefore, finding an early markers 
of CV risk are important. We demonstrated no differences in EPC 
numbers and function between a DPP4i and a well-established 
antidiabetes medication. Our results echo the clinical data from trials 
published after our research was begun supporting a neutral CVD profile 
of Saxagliptin as an adjunct to the treatment of T2DM. 
The preliminary results of this study were published as a poster 
publication in the International Congress of Endocrinology/ENDO 
(ICE/ENDO) 2014, Chicago, USA, June 2014 (Poster MON-1051) and 
the Irish Endocrine Society (IES) 39th Annual Meeting 14th – 15th 
November 2014 (POSTER 3) (Appendix section 4.1.3).  
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3 Study 2: The Effect of Taurine on Endothelial Dysfunction In 
Type 2 Diabetes Mellitus: A Pilot Study 
3.1 Introduction 
There is a two- to three-fold increase in cardiovascular (CVD) mortality in 
T2DM patients compared to aged-matched non-diabetic subjects(5). 
Addressing coexisting risk factors such as hypertension, 
hypercholesterolaemia and obesity are cornerstones in reducing CVD 
mortality(109).  
The earliest detectable finding in the pathogenesis of atherosclerosis is 
endothelial dysfunction(5). Cardiovascular risk factors contribute to 
endothelial injury, disrupting the balance between nitric oxide (NO) and 
potent vasoconstrictor oxidants, resulting in the inability to maintain 
vascular tone and reactivity(269). This stiff artery increases ventricular 
pressure and further attenuates NO production and promotes more 
atheromatous plaque production(196). Arterial stiffness has been shown 
to be a strong independent predictor of future CV events and all cause 
mortality in general population(6).  
Taurine is a sulfur-containing amino acid, synthesized in the body in 
limited amounts, but also present in food, with largest quantities in 
seafood(8, 9). It has been shown to have a beneficial effect in 
hypertension(10, 11), hypercholesterolaemia(12, 13), the rate of 
progression of diabetic nephropathy(249) and endothelial function in 
animal models of diabetes(14, 15). Potential relevance to human 
disease was shown by the WHO-CARDIAC Study of taurine levels in a 
24-population sample worldwide. The Japanese population in this study 
had higher taurine levels than the Chinese, European, North American 
and Oceanic Caucasians. This cross-sectional study demonstrated for 
the first time, an independent inverse association between population 
levels of taurine excretion and ischaemic heart disease (IHD) 
mortality(8).  
Taurine exerts its effect through its antioxidant properties.  It reacts to 
the hydrogen peroxide-myeloperoxidase-chloride (HCIO) system, 
 97 
reduces the oxidative damage by LDL, regulates mitochondrial function, 
inhibits reactive oxygen species (ROS) and further increases the 
bioavailability of nitric oxide (NO)(9, 233, 240). Studies in diabetes have 
shown that taurine levels are lower in diabetes patients compared to 
non-diabetic controls(255-257). Furthermore, diabetes and its 
complications are strongly associated with the excess of oxidative stress, 
reduced mobilization of endothelial progenitor cells (EPC) and vascular 
damage(172).  
Endothelial dysfunction is also associated with reduced numbers of 
EPCs(7). EPCs are circulating bone marrow derived cells, which have the 
ability to promote vasculogenesis and repair damaged blood vessels(17). 
All risk factors for atherosclerosis have been associated with reduced 
numbers and/or dysfunction of circulating EPCs, while an expanded EPC 
pool is associated with a decreased cardiovascular mortality. (1, 7, 78, 
264, 265). EPC numbers in patients with T2DM have been shown to be 
significantly lower than in non-diabetic subjects(86) and the levels of EPC 
acts as a surrogate biological marker for vascular function and cumulative 
cardiovascular risk(7). ROS in diabetes plays an important role in down-
regulating hypoxia inducible factor (HIF)-1α resulting in inability to 
mobilize EPC from the bone marrow in response to tissue ischaemia(172, 
174, 175). 
There are only limited data on the effect of taurine supplementation and 
EPC. Taurine has been reported to suppress sympathetic tone and 
attenuates EPC senescence(270). Fennessy et al evaluated the 
monocyte-endothelial interactions using the monocyte derived from 
young smokers (monocyte-condition medium, MDM) on human umbilical 
vein endothelial cells (HUVECs). In that study, taurine up-regulated the 
level of nitric oxide synthase expression, normalized the level of NO, 
suppressed endothelin-1 and contributes to improvement in flow-
mediated dilatation (FMD) of brachial artery in young smokers(263). In 
that study, monocytes were not cultured for the development of EPC, 
hence the numbers and functions of EPC were not assessed.  
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The first study of taurine intervention in diabetes was published by 
Moloney et al who demonstrated that 2 weeks of taurine 
supplementation in Type 1 diabetes patients, improved flow mediated 
dilatation (FMD), pulse wave velocity (PWV) and augmentation index 
(AIx)(16), a well-validated, non-invasive technique to evaluate 
endothelial dysfunction and arterial stiffness(196, 271). 
We hypothesized that taurine supplementation may have similar benefits 
in T2DM patients. We carried out a pilot study using a randomized, 
double blind, cross-over placebo design. We examined the effects on 
endothelial dysfunction by measuring the levels of EPCs and PWV.  
3.2 Methods 
Participants were identified when they attended routine clinic visits at the 
diabetes outpatient clinic and the diabetes day centre at Connolly 
Hospital from December 2012 to April 2013. The study was discussed 
and a patient information leaflet was given (Appendix section 4.2.1). 
Participants who agreed to the study were given an appointment to attend 
the diabetes day centre, where full informed consent was obtained.  
The inclusion criteria included stable, well controlled type 2 diabetes 
(HbA1c < 6.5% or 48mmol/mol), on diet treatment alone or on stable 
dose of anti-diabetic treatment/s for the last 3 months, and aged 
between 18 to ≤ 65 years old.  
 
Participants with evidence of renal impairment (cc <60 mL/min) , 
presence of microalbuminuria, having intercurrent illness, uncontrolled 
hypertension (treated or untreated), foot ulcer, any retinopathy, active 
infection, any malignancy, recent (within last 6 months) myocardial 
infarction, heart failure, or stroke, peripheral vascular disease or absent 
peripheral pulses, history of psoriasis, seizure or epilepsy, previous 
hypersensitivity to taurine supplement, pregnant and breast feeding 
women, children or minors under 18 years old, and cognitively impaired 
persons were excluded from the study.  
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All participants signed an informed consent (Appendix section 4.2.2) and 
this study was approved by the Connolly Hospital Ethics Committee 
(Appendix section 4.2.3)  
On the first visit (day 0), participants had anthropological measurements 
such as weight, height, body mass index (BMI), waist circumference, hip 
circumference, waist to hip ratio (WHR), clinical assessment (medical 
history, medications, blood pressure), routine fasting blood testing (renal/ 
liver/ bone profile, HbA1c, cholesterol), blood sampling for EPC culture, 
and carotid femoral PWV. Height and weight were measured without 
shoes and rounded to the closest 0.5cm and nearest kg. Waist 
circumference was measured using non-stretchable tape, while standing, 
feet together, midpoint between lower rib margin and iliac crest.  
By using a random number generator, each participant was randomly 
assigned either Taurine 500mg or placebo supplementation three times 
daily. Participants were advised not to change any dietary habits during 
the study. 
On the intermediate visit (day 30), participants had similar 
measurements, clinical assessments, blood tests including extra sample 
for EPC evaluation and PWV measured. Any remaining tablets were 
counted as a proxy to evaluate compliance. After 2 weeks washout, 
participants were then assigned in a crossover fashion to the opposite 
supplement for another 30 days.  
These tests were repeated when participants returned for the final visit 
(day 60). Throughout this time, participants were free to contact the 
investigators if they become unwell after taking either supplement.  
A person independent of the study was assigned to manage the 
randomization code, storage, dispensing and recording supplements 
assigned to participants at baseline and intermediate visit. This code was 
kept securely and the participant was only unblinded in the event of an 
adverse event.  
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At each visit, participants had blood drawn for endothelial progenitor cells 
analysis (EPC). The method for EPC cells culture and adhesion assay 
was described previously (Section 4.3).  
A single operator measured the Carotid-Femoral PWV (cfPWV) in all 
participants.  This was performed under a standardized condition as 
described by the 2006 expert consensus(198). Participants fasted from 
midnight and refrained from smoking 3 hours before measurement. The 
test was performed in a supine position, after 10 minutes rest, in a quiet 
room with stable temperature of 210c. We used the Vicorder® Vascular 
Complete device (Skidmore Medical, Bristol UK) which uses oscillometric 
techniques to detect a pulse waveform. This device has been validated 
against the SphygmoCor device in various studies(272-275). To detect 
the femoral pulse, a 100mm wide blood pressure cuff was placed around 
the right upper thigh while a smaller 30mm partial cuff was placed around 
the neck at the level of right carotid artery for the detection of carotid 
pulse. Blood pressure and the distance between suprasternal notch to the 
upper limit of femoral cuff were measured and recorded in the software 
provided. Each participant had three measurements performed and 
average readings were calculated and used for analysis. PWV is 
expressed in meter per seconds (m/s).  
Taurine capsules were sourced from Lambert Healthcare Ltd (UK), 
manufactured by Thompson and Capper Ltd (Appendix section 4.2.4) 
while placebo (Microcrystalline Cellulose) capsules were sourced from 
Mawdsley Brooks and Co (UK) (Appendix 4.2.4). Taurine was 
encapsulated in Hydroxypropyl Methylcellulose (HPMC) while placebo 
was encapsulated in gelatin. Both are common material used for capsule 
manufacturing and are known to mask taste and odour from active 
ingredient(276, 277). Only the independently assigned person 
responsible for managing the randomization code had direct access to 
both Taurine and placebo capsules. Neither company provided any 
financial support to this study.  
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3.3 Statistical Analysis 
Data were analyzed based on treatment group. Normally distributed data 
are expressed in mean ± SD while skewed data are expressed in median 
and interquartile range (IQ range). One-way analysis of variance 
(ANOVA) with post-hoc Tukey-Kramer was used when comparing 
normally distributed data between groups while Kruskal-Wallis test was 
used for skewed data. The p <0.05 was set as a significant level. All 
participants were entered into the study on an intention-to-treat basis and 
no subject was removed or dropped from the study.  
3.4 Results 
A total of 11 participants, 8 males and 3 females, were enrolled in the 
study. Due to technical reasons, 1 participant did not have the EPC result 
after Taurine supplementation while 1 participant did not have EPC 
adhesion study at baseline.  
Table 3-1 demonstrates the baseline characteristics of all participants in 
the study. The median age was 59.7 (56.7 - 61.7) years old with a mean 
diabetes duration was 4.4 ± 3 years. Mean waist-hip ratio (WHR), systolic 
blood pressure (SBP), diastolic blood pressure (DBP), LDL cholesterol 
(LDL) and triglycerides (TG) were 0.96 ± 0.06, 138.7±18.2 mmHg, 
86.3±10.2 mmHg, 1.97±0.63mmol/L and 1.81±1.12 mmol/L. Median body 
mass index (BMI), glycated Haemoglobin (HbA1c), total cholesterol (TC), 
and HDL cholesterol (HDL), were 30.5 (27.8 – 32.7) kg/m2, 44 (43-48) 
mmol/mol, 4.2 (3.5-4.9) mmol/L, and 1.4 (1.31-1.5) mmol/L. Majority of 
the participants (81.8%) were on aspirin, statin and metformin  while only 
4 (36.4%) participants were on antihypertensive/s including Angiotensin 
Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker 
(ARB). A total of 2 participants (18.2%) were smoker at baseline. 
Baseline PWV was 8.7 (8.0-10.7) m/s while total EPC per high power 
field (EPC/hpf) and EPC adhesion capacity were 32 ± 8 cells/hpf and 
0.66 ± 0.4 fluorescence unit respectively.  
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Table 3-1:  Parameters at baseline. Normally distributed data are 
expressed as mean ± SD while skewed data are expressed as median 
(interquartile range, IQ range). ACEI (Angiotensin Converting Enzyme 
Inhibitor), ARB (Angiotensin Receptor Blocker), BMI (Body Mass Index), 
HbA1c (Glycated Haemoglobin), ACR (Albumin Creatinine Ratio), HDL 
(High Density Lipoprotein), LDL (Low Density Lipoprotein), EPC 
(Endothelial Progenitor Cells). 
Baseline Characteristics Values 
Total participants 11 
Age (years) 59.7 (56.7-61.7) 
Diabetes Duration (n, years) 9 (4.4 ± 3.0) 
Gender (n, %) 
Male 
Female 
 
8 (72.7) 
3 (27.3) 
BMI (kg/m2) 30.5 (27.8 – 32.7) 
Waist Hip Ratio (WHR) 0.96 ± 0.06 
Systolic Blood Pressure (mmHg) 138.7 ± 18.2 
Diastolic Blood Pressure (mmHg) 86.3 ± 10.2 
Concomitant Medications (n, %) 
Statin 
Aspirin 
Antihypertensive 
ACEi or ARB 
Metformin 
 
9 (81.8) 
9 (81.8) 
4 (36.4) 
4 (36.4) 
9 (81.8) 
Smoker (n, %) 2 (18.2) 
Fasting glucose (mmol/L) 6.33 ± 0.97 
Glycated Haemoglobin, HbA1c 
(mmol/mol) 
44 (43-48) 
Creatinine (mmol/L) 70.3 ± 9.3 
Urine ACR (mg/mmol) 1.02 ± 0.38 
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Baseline Characteristics Values 
Total Cholesterol (mmol/L) 4.2 (3.5-4.9) 
HDL Cholesterol (mmol/L) 1.4 (1.3-1.5) 
LDL Cholesterol (n, mmol/L) 10, 2.0 ± 0.6 
Triglycerides (mmol/L) 1.8 ± 1.1 
Pulse Wave Velocity (m/s) 8.7 (8.0-8.4) 
EPC per high power field (EPC/hpf, 
cells) 
32 ± 8 
EPC adhesion (fluorescence unit) 10, 0.66 ± 0.4 
 
Table 3-2 demonstrates the comparison of measured parameters 
between baseline, post taurine and post placebo. There were no 
significant differences in body mass index (BMI), waist-hip ratio (WHR), 
SBP, DBP, Creatinine, Alb/Creat ratio, fasting glucose, HbA1c, TC, HDL, 
LDL, TG levels between groups.  
There was a trend towards improvement in the number of EPC/hpf 
following taurine (40 ± 7 cells) and placebo (37 ± 10 cells) when 
compared to baseline (32 ± 8 cells, p=0.08) (Table 3-2, Figure 3-1). 
Similarly, there was a trend towards improvement in DBP following 
taurine (78.6 ± 7.4 mmHg) and placebo (79.3 ± 7.5 mmHg) when 
compared to baseline (86.3 ± 10.2mmHg, p=0.08) (Table 3-2, Figure 3-
2). There were no differences in the EPC adhesion capacity between 
baseline (n=10, 0.66 ± 0.4 fluorescence unit), taurine (10, 0.97 ± 0.8 
fluorescence unit) and placebo (11, 0.94 ± 0.5, p=0.43 fluorescence unit) 
group. There were also no differences in the measurements of PWV 
baseline [8.7 (8.0-8.4) m/s], taurine [9.1 (8.3-9.6) m/s] and placebo [8.9 
(8.8-9.1) m/s, p=1.0] (Table 3-2).  
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Table 3-2 Comparison between changes in parameters at baseline, after 
Taurine and Placebo supplementations. Normal data are expressed as mean ± 
SD while skewed data are expressed as median (interquartile range, IQ range). 
Unless stated (n) before mean and median values, there are 11 participants per 
group. Trends of improvement in DBP and EPC numbers per hpf following 
intervention. BMI (body mas index), WHR (waist-hip ratio), SBP (systolic blood 
pressure), DBP (diastolic blood pressure), Creat (Creatinine), Alb (Albumin), 
HbA1c (Glycated Haemoglobin), TC (Total Cholesterol), HDL (High Density 
Lipoprotein), LDL (Low Density Lipoprotein), TG (Triglycerides), PVW (Pulse 
Wave Velocity), EPC (Endothelial Progenitor Cell), hpf (high power field). 
Significant difference at p value < 0.05. 
Parameters Baseline Taurine Placebo Sig 
Age (years) 59.7 (56.7-
61.7) 
- - - 
Compliance (%) - 95.2 (92.8-
100) 
96.8 (86.5-
100) 
0.72 
BMI (kg/m2) 35.2 ± 5.1 34.9 ± 4.8 35.6 ± 5.7 0.96 
WHR 0.96 ± 0.06 0.97± 0.06 0.96 ± 0.05 0.87 
SBP (mmHg) 138.7 ± 18.2 132.1 ± 15.2 136 ± 17 0.65 
DBP (mmHg) 86.3 ± 10.2 78.6 ± 7.4 79.3 ± 7.5 0.08 
Creat (µmol/L) 70.3 ± 9.3 67.7 ± 10.7 69.6 ± 11 0.84 
Alb/Creat ratio 
(n, mg/mmol) 
11, 1.02 ± 
0.38 
8, 1.01 ± 0.51 10, 1.09 ± 
0.45 
0.91 
Fasting glucose 
(n, mmol/L) 
11, 6.33 ± 
0.97 
8, 6.23 ± 0.62 9, 61.9 ± 0.9 0.93 
HbA1c 
(mmol/mol) 
44 (43-48) 44 (43-47) 44 (43-47) 0.99 
TC (mmol/L) 4.2 (3.5-4.9) 3.8 (3.6-4.7) 3.9 (3.4-4.5) 0.65 
HDL (mmol/L) 1.4 (1.3-1.5) 1.4 (1.2-1.6) 1.4 (1.2-1.4) 0.97 
LDL (n, mmol/L) 10, 2.0 ± 0.6 11, 2.1 ± 0.7 11, 2.1 ± 0.8 0.88 
TG (mmol/L) 1.8 ± 1.1 1.6 ± 0.7 1.4 ± 0.8 0.5 
PWV (m/s) 8.7 (8.0-8.4) 9.1 (8.3-9.6) 8.9 (8.8-9.1) 
 
1.0 
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Parameters Baseline Taurine Placebo Sig 
EPC/hpf (n, 
cells) 
11, 32 ± 8 10, 40 ± 7 11, 37 ± 10 0.08 
EPC Adhesion 
(n, fluorescence 
unit) 
10, 0.66 ± 0.4 10, 0.97 ± 0.8 11, 0.94 ± 0.5 0.43 
 
 
Figure 3-1 Comparing numbers of EPC per high power field (EPC/hpf) 
based on treatment groups (Study 2). Single horizontal line in the bar 
represents mean value while error bar represent 95% confidence interval. 
Clear circles represent outliers. There was a trend of improvement in the 
number of Endothelial Progenitor Cells (EPC) per high power fields (hpf) 
following intervention with p = 0.08. 
 106 
 
 
Figure 3-2 Comparing diastolic blood pressure (DBP) based on treatment 
groups (Study 2). Single horizontal line in the bar represents mean value 
while error bar represent 95% confidence interval. There was a trend of 
improvement in Diastolic Blood Pressure following intervention with 
p=0.08. 
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3.5 Discussion 
In this pilot study, we demonstrated no significant difference between the 
effects of Taurine and placebo supplementation on markers of endothelial 
dysfunction and arterial stiffness assessed using EPC and PWV in 
patients with T2DM. This result may be interpreted as an absence of 
benefit of Taurine in modulating known markers of endothelial dysfunction 
in T2DM. However, we also demonstrated a downward trend in DBP and 
an upward trend in the numbers of EPC with intervention.  
To our knowledge, this is the first study evaluating the effect of Taurine 
on EPC and arterial stiffness in patients with T2DM. Two previous taurine 
intervention studies in T2DM evaluated the effects of taurine on 
glycaemic control and biomarkers of fibrosis(258, 278).  
3.5.1 Comparison with T1DM Study 
The closest study to compare to, involved participants with T1DM as 
published by Moloney et al. (16).  
Our cohort of T2DM was older but had better overall glycaemic control. 
Our cohort had higher BMI while participants with BMI ≥ 30kg/m2 were 
excluded from the T1DM study. Similarly, 2 of our participants were 
smokers and continued to smoke throughout the study while smoker was 
excluded in the T1DM study. Concomitant medications were not reported 
in the T1DM study, while most of our participants were on statin, aspirin, 
metformin and antihypertensive at baseline.  
These unavoidable differences may contribute to the differences in the 
degree of arterial stiffness in our cohort compared to the T1DM cohort. 
Our cohort is likely to have longer duration of arterial stiffness as 
demonstrated by studies showing a stepwise progression from pre-
diabetes state towards diabetes and the strong association between 
arterial stiffness and insulin resistance(279-281).  
For the measurement of arterial stiffness, instead of Augmentation Index 
(AIx) and Flow-Mediated Dilatation (FMD), we performed PWV, as it is 
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the current gold standard, especially in subjects with diabetes(197). 
Additionally, our device was less-operator dependent, well validated, and 
have been shown to be highly reproducible (272-275, 282).  
We used a similar dose of taurine, allowed a similar washout period and 
performed similar comparison analyses between the groups of treatment. 
As each participant acts as his/her own control, we elected not to recruit a 
control, non-diabetic cohort.  
Similar to other studies(16, 242), we did not perform a second baseline 
after two weeks washout, as it was considered adequate for complete 
elimination of active treatment(241, 242).  
3.5.2 Discussion of Literature in Relation to Study Results 
Our result did not show any significant difference to the markers of 
endothelial dysfunction (EPC and PWV) following supplementation with 
taurine compared to placebo and baseline.  
Although there is an abundance of evidence linking diabetes and arterial 
stiffness, there have been only a few studies examining the changes in 
arterial stiffness with intervention in T2DM subjects(197).  A systematic 
review of trials with Pioglitazone demonstrated a composite benefit in 
arterial stiffness as measured using PWV(283). More recently, Davenport 
et al demonstrated that statin improves arterial stiffness, measured using 
PWV at 3 and 12 months follow up with no dose-dependent effect 
observed(284). The results from our intervention study in T2DM will add 
to the body of evidence in this area.  
The trend of improvement in EPC and DBP following intervention 
especially with taurine was intriguing. Previous animal studies did 
demonstrate that taurine depletion leads to salt-induced hypertension 
while supplementation of taurine attenuates this response(237, 285, 286). 
However, there are very limited clinical studies on the antihypertensive 
effect of taurine on blood pressure(10). One such study demonstrated a 
reduction of SBP and DBP by 9mmHg and 4mmHg respectively after 
6g/day of taurine supplementation for 1 week(287). In a recent 
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prospective, double-blinded, placebo control study, 120 pre-hypertensive, 
non-diabetic participants were randomized to either taurine 1.6g/day for 
12 weeks demonstrated an improvement in the clinic and 24 hour 
ambulatory blood pressure measurement, compared to placebo(11). In 
the same study, taurine also improves the level a vasodilator hydrogen 
sulfide (H2S), another potential mechanism of the antihypertensive effect 
of taurine (11). Furthermore, in an animal model of diabetes, restoration 
of H2S in improves wound healing in by restoring EPC function(288).  
Further clinical studies involving intervention with taurine in T2DM with 
measurements of H2S would be the next important step to characterize 
the potential benefit of taurine in this group.  
The optimum dose for taurine supplementation in order to exert any 
clinical effect is not known. Taurine doses up to 3g per day have been 
shown to elevate plasma taurine level in T2DM without any effect on 
glycaemic control(258). It is not known if the same dose or more is 
needed to have any significant effect on EPC or arterial stiffness in 
patients with T2DM. The dose of 1.5g per day is the most commonly used 
in other human studies (16, 242, 260, 263), although it is a lower dose 
when compared to animal studies where taurine dose may reach more 
than 10 times per body weight of the animal(9). 
Despite previous experimental data supporting its role as an antioxidant, 
the effect of taurine on EPC has never been studied. Although Fennessy 
et al used similar techniques to our study, in a group of young 
smokers(263), the cells were not cultured to the level of EPC, so 
comparisons with our study cannot be made.  
While EPC and PWV are independent early predictors of CVD, in a lower 
risk group, EPC continues to predict CVD better than the Framingham 
score (6, 7, 38, 78). However, only several studies are available where 
EPCs were measured with PWV in patients with diabetes(222-224). 
Similarly, only limited publications are available, where improvement of 
PWV with intervention were demonstrated in T2DM, mostly derived from 
a high-risk diabetes subjects(197, 283, 284). For this pilot study, our 
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participants were of T2DM patients with low-risk for CVD. At baseline, our 
participants had excellent blood pressure control, no microalbuminuria 
and a median cfPWV of 8.7 (IQ 8.0-8.4) m/s which was lower than the 
2010 (202) and the 2011 recommended threshold of 10m/s (201). The 
majority of our participants were on multidrug therapy including statins, 
which have been associated with 15% to 35% improvement of EPC(82-
85, 289). It is possible that in this low risk group, with multidrug treatment, 
the EPC pool is recovering. Although there was a trend of EPC 
improvement with intervention, there was no difference in PWV 
suggestive of no changes in arterial stiffness, at least in our cohort. Our 
data adds to the limited publications available examining the link between 
EPC and PWV with intervention.  
3.5.3 Limitations and Strengths 
Our sample size was small and our study duration in each intervention 
was short. We could not outrule a potential type-1 error contributing to the 
downward trend in DBP and an upward trend in the numbers of EPC with 
intervention. As this was a pilot study in T2DM, we based it on the 
previously published T1DM study by Moloney et al, who had fewer 
participants. Our study will serve as a preliminary to future studies in 
Taurine with T2DM. 
We did not perform a second baseline measurement after the 2 weeks 
washout period and although previous publications support the duration 
of active drug withdrawal as being adequate, we cannot completely 
outrule the possibility of remaining active ingredient affecting our results. 
We strongly advised our participants not to change their dietary habit 
during the study. However, by not measuring serum taurine, we cannot 
outrule any influence if any, of dietary taurine on the results. Future 
studies needs to involve more participants preferably with higher risk 
T2DM, in a prospective placebo control design and with the measurement 
of serum and urinary excretion of taurine. 
Our study is the first to evaluate the effects of taurine on EPC and arterial 
stiffness in T2DM participants. There is insufficient evidence 
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characterizing the interaction between reversibility of arterial stiffness with 
intervention, the effects of taurine on EPC and blood pressure, and the 
interaction between EPC and PWV. The trend of improvement of EPC 
and DBP following intervention, especially with taurine, potentially 
through the restoration of H2S needs to be further examined.  
3.5.4 Summary 
In summary, in comparison to placebo, supplementation of taurine for 30 
days did not exert any significant effects on EPC numbers, adhesion 
capacity, and PWV, which are known markers of endothelial dysfunction. 
More studies are needed with bigger sample size, longer duration, and 
with different risk factor profiles to further characterize any potential role 
of taurine as a modulator of CV risk in T2DM. 
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4 Appendix 
4.1 Study 1 
4.1.1 Patient Information Leaflet 
 
      
 
Patient Information Leaflet:  
The Effect of DPP4 inhibitor or Sulphonylurea on Endothelial 
Progenitor Cells in Type 2 Diabetic Patients 
Cardiovascular disease (e.g heart attack, or stroke) are important 
complications of diabetes. Controlling risk factors for these complications, 
such as high cholesterol and high blood pressure, and stopping smoking 
have been shown to reduce the risk of developing these complications.   
Endothelial Progenitor Cells (EPCs) are cells which circulate in the blood 
which are thought to be responsible for forming new blood vessels in 
adults if necessary and also repairing any damage to blood vessels. 
There is limited information regarding the effect of different diabetes 
treatments on the number of EPCs in the bloodstream.  
Sulphonylurea (Gliclazide MR) is a well-established anti-diabetic 
medications used for the last 60 years. It is licensed as a second line 
tablet for treatment of diabetes. 
DPP4 inhibitor (Saxagliptin) is a new medication for diabetes patients. It 
is a tablet that has been proven to be very effective in reducing blood 
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sugar level. It is licensed to be use as a second line medication in treating 
diabetes.  
We plan to examine the effect of Saxagliptin and Gliclazide MR on EPC 
number and function in patients with diabetes. The results of the study 
may give us a clue as to the effects of these medications on the risk of 
having cardiovascular disease in the future. 
You have been invited to participate in this study as you need additional 
treatment for your diabetes, and either Gliclazide or Saxagliptin have 
been considered to be good treatment choices for you. If you agree to 
take part in this study, you will be allocated randomly to either receive 
Gliclazide MR or Saxagliptin.  
The most common side effects from Gliclazide MR are low blood sugar 
(hypoglycaemia) and gastrointestinal disturbance. You will need to check 
your blood sugar more frequently while on this medication. Saxagliptin 
may also cause low blood sugar but not as frequently as Gliclazide MR. It 
may also cause gastrointestinal disturbance, dizziness and muscle 
aches. Both medications are well tolerated in general. 
Before commencing treatment, we will perform routine clinical 
examination including examination of your eyes, recording blood 
pressure, height, weight and waist to hip ratio. We will take blood 
samples to grow EPCs and we will also check cholesterol, glucose, 
HbA1c, kidney, liver, and bone profile level. After 6 months, you will have 
similar clinical examinations and similar blood sample will be taken. All of 
this should not take much more than 30 minutes at each visit. All of your 
details will be kept confidential. There will be no need for any further visits 
apart from your usual hospital visits.  
Participation in this study is entirely voluntary and you may withdraw at 
any time, without giving reason, and without this decision effecting any 
future treatment or medical care. 
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Our responsibilities as investigators:  
If you experience any ill effects as the result of your participation, then we 
will take care of your medical needs.  If we discover any medical 
problems such as high blood pressure or cholesterol, this would be 
discussed with you in detail, and you would be offered appropriate 
treatment and follow up in a specialist clinic or with your GP.   
If there are any new findings during the course of the study that may 
affect the validity of the study or your participation in it, then the findings 
will be made available to you and you will receive the appropriate medical 
care and advice depending on the test results.   
Confidentiality:  
Only anonymous data, ie. data that do not identify you by name, will be 
collected. Only authorised representatives of the study team will have 
direct access to your personal medical records. All study team 
representatives and medical staff are obliged to maintain confidentiality at 
all times.  The data shall be destroyed by shredding and deletion of 
computer files at the end of the study 
 
For additional information now or any future time please contact:  
Dr. Wan Aizad Wan Mahmood, Research Registrar  
Connolly Hospital, Blanchardstown, Dublin 15.  Phone: 01 646 5756 
Dr. John McDermott, Consultant Endocrinologist 
Connolly Hospital, Blanchardstown, Dublin 15.  Phone: 01 646 5758 
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4.1.2 Consent Form  
      
CONSENT FORM 
 
Protocol Title:  The Effect of DPP4 inhibitor or Sulphonylurea on 
Endothelial Progenitor Cells in Type 2 Diabetic Patients 
 
Please tick the appropriate answer. 
 
• I consent to take part in this study.   Yes  No  
          
• I confirm that I have read and understood the Patient Information 
Leaflet attached (version 1, 23/08/2010), and that I have had ample 
opportunity to ask questions all of which have been satisfactorily 
answered.                                      
        Yes  No  
 
• I have been given a copy of the Patient Information Leaflet and this 
Consent form for my records.       
        Yes  No 
 
• I understand that my participation in this study is entirely voluntary 
and that I may withdraw at any time, without giving reason, and 
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without this decision affecting my future treatment or medical care.
         Yes  No 
 
• I understand that my medical records may be viewed by members of 
the research team       
         Yes  No 
 
• I understand that my identity will remain confidential at all times. 
         Yes  No 
• I am aware of the potential risks of this study.   
         Yes  No 
 
• I agree that I will not restrict the use to which the results of this study 
may be put. I give my approval that anonymous data concerning my 
person may be stored or electronically processed for the purpose of 
scientific research and may be used in related or other studies in the 
future. (This would be subject to approval by an independent body 
which safeguards the welfare and rights of people in biomedical 
research studies - the Connolly Hospital Ethics (Medical Research) 
Committee.)        
         Yes  No 
 
• I consent for further follow-up studies 
 Yes  No 
 
Patient ___________________________      
 
___________________________________________________ 
 Signature and dated   Name in block capitals 
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To be completed by the Principal Investigator or his nominee.  
 
I the undersigned, have taken the time to fully explain to the above 
patient the nature and purpose of this study in a manner that he/she 
could understand. I have explained the risks involved, as well as the 
possible benefits and have invited him/her to ask questions on any aspect 
of the study. 
 
 ___________________________________________________ 
Signature, qualifications and date  Name in block capitals 
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4.1.3 Poster publication 
  
Cardiovascular Safety of DPP-4 inhibition in Patients with Type 2 
Diabetes Mellitus: Endothelial Progenitor Cells as an Early Marker of 
Long-term Cardiovascular risk!
WA Wan Mahmood, TF King, T Kyaw Tun, S Sreenan, JH McDermott!
Department of Endocrinology and Diabetes, Connolly Hospital, Blanchardstown, 
Dublin 15, Ireland!
Disclosure: Authors have no potential conflict of interest!
BACKGROUND 
 
Endothelial Progenitor Cells (EPCs) are 
circulating bone-marrow derived cells 
which promote post-natal vasculogenesis. !
!
EPCs play a central role in cardiovascular 
repair and studies have demonstrated a link 
between EPC number and function and 
future cardiovascular risk[1]. !
!
Interventions which modify cardiovascular 
risk have early effects on EPC number and 
function [2]. !
!
Recently there has been increased 
appreciation of the need to evaluate 
cardiovascular safety of new anti-diabetic 
agents, but long-term post-marketing trials 
are often required before an adverse 
cardiovascular signal is seen.!
!
DPP-4 inhibitors are effective glucose-
lowering agents, but their long-term 
cardiovascular safety has not been 
extensively tested.  
!
We aimed to evaluate the long-term 
cardiovascular safety of Saxagliptin (SAX, 
a DPP-4 inhibitor) versus Gliclazide 
Modified Release (GLC) using EPC 
number and function as surrogate markers 
of cardiovascular risk !
!
PATIENTS AND METHODS!
!
18 patients with T2DM on Metformin 
monotherapy requiring diabetes treatment 
intensification were randomized to SAX 
(n=7) or GLC (n=11) in an open-label 
fashion.  !
!
EPC number and adhesion capacity were 
measured, using methods as previously 
described [3], at baseline and 6 months 
after treatment. !
!
At each visit, additional fasting blood tests 
for HbA1c, renal profile, glucose, fasting 
lipids and urine albumin creatinine ratio 
(UAC) were performed.!
Table 1 Saxagliptin 
( n = 7 ) 
Gliclazide 
MR ( n = 11 ) 
P value 
Gender, n(%) 
Female 
Male 
 
1 (14.3) 
6 (85.7) 
 
5 (45.5) 
6 (54.5) 
 
0.39 
Smoker, n(%) 0 3 (30) 0.34 
Age (mean ± SD years ) 57.89 ± 6.1 55.53 ± 8.61 0.54 
BMI (mean ± SD kg/m2 ) 29.35 ± 1.77 30.67 ± 3.37 0.36 
WHR (mean ± SD ) 0.94 ± 0.33 0.97 ± 0.83 0.33 
SBP (mean ± SD mmHg ) 145.14 ± 28.1 139.45 ± 
19.74 
0.62 
DBP (mean ± SD mmHg ) 88.43 ± 14.52 83.91 ± 10.68 0.46 
Diabetes duration (mean ± 
SD years ) 
4.86 ± 2.67 3.64 ± 2.01 0.29 
Creatinine (mean ± SD 
years ) mmol/L 
88.9 ± 15.2 63.5 ± 14.5 0.003 
Glucose (mean ± SD 
years ) mmol/L 
7.54 ± 0.73 8.81 ± 1.75 0.16 
HbA1c (mean ± SD years ) 
mmol/mol 
53.1 ± 4.4 62.2 ± 8.8 0.02 
Total EPC per HPF [med 
(IQ range)] cells 
35 (21 – 54) 25 (22 – 46) 0.6 
EPC Adhesion capacity 
[med (IQ range)] 
fluorescence units  
0.22 (0.17 – 
0.85) 
0.27 (0.1 – 
0.67) 
0.8 
Table 1: Comparing baseline parameters based on treatment. Table 2: Comparing 
treatment group at 6 months to baseline 
BMI = Body Mass Index, WHR = waist-hip ratio, SBP = Systolic Blood Pressure, 
DBP = Diastolic Blood Pressure, HbA1c = Glycosylated Haemoglobin. 
Significance value p<0.05. 
RESULTS!
Table 2 Saxagliptin 
( n = 7 ) 
Gliclazide MR 
( n = 11 ) 
HbA1c (mean ± SD), mmol/mol 
Baseline 
6 months 
Sig 
 
53.1 ± 4.4 
50.4 ± 6.6 
0.33 
 
62.9 ± 9.0 
58 ± 8.3 
0.13 
Weight (mean  ±  SD), kg 
Baseline 
6 months 
Sig 
 
84.2  ±  10 
84.5  ±  9.6 
0.8 
 
86  ±  14.7 
87.9  ±  14.9 
0.008 
EPC number [med (IQ range)], 
cells/HPF 
Baseline 
6 months 
Sig 
 
 
35 (21 – 54) 
35 (28 – 38) 
0.5 
 
 
25 (22 – 46) 
39 (28 – 46) 
0.24 
EPC adhesion capacity [med (IQ 
range)], fluorescence units 
Baseline 
 
6 months 
 
Sig 
 
 
0.2 (0.17 – 
0.86) 
0.3 (0.17 – 
0.65) 
1.0 
 
 
0.27 (0.1 – 
0.67) 
0.32 (0.14 – 
0.84) 
0.9 
SUMMARY!
!
We found no difference in EPC 
numbers or adhesion capacity 
in patients treated with 
Saxagliptin vs Gliclazide MR 
for 6 months!
!
This may suggest a similar 
cardiovascular safety profile of 
Saxagliptin to Gliclazide MR, a 
well-established treatment for 
type 2 diabetes!
!
REFERENCES!
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A!
B!
Figure 1A : EPC at high power field (400x). !
Figure 1B : EPC adhesion assay (100x)!
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4.2 Study 2 
4.2.1 Patient Information Leaflet 
 
             
    
 
Patient Information Leaflet:  
The Effect of Taurine on Endothelial Dysfunction in Patients with 
Type 2 Diabetes. 
Diabetes is a chronic condition associated with complications such as 
blindness, kidney failure, impaired sensation, heart attack and strokes. 
The risk of having stroke and heart attack in type 2 diabetes (T2DM) 
patients is increased by two to three fold compared to people without 
diabetes.  
Central to this complication is the blood vessel. Cells called endothelial 
cells form blood vessels. Blood vessel problems (i.e. stiff or narrowed 
blood vessel) are more common in diabetes patients and contribute to 
heart attack and strokes.  
Taurine is a type of protein present in seafood and has been shown in 
some studies to be protective for endothelial cells against damage. 
Endothelial Progenitor Cells (EPCs) are cells that come from bone 
marrow and mature into endothelial cells. They circulate in the blood and 
they are thought to be responsible for forming new blood vessels in adults 
and also repairing any damage to blood vessels. Patients with diabetes 
have lower EPCs number compared to non-diabetic patients, which may 
lead to blood vessel dysfunction subsequently heart attack and strokes.  
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Recently, a group of researcher from Royal College of Surgeons in 
Ireland (RCSI) have shown that supplementation of taurine three times 
daily improves the function of blood vessel and improve the function of 
EPCs in Type 1 diabetes patients. 
We plan to replicate a similar study in Type 2 diabetes patients. We want 
to see if taurine supplementation in Type 2 diabetes patients will show the 
same effects.  
You have been invited to participate in this study, as you appear to be a 
suitable patient based on predefined criteria.  
This study is a double blinded randomized cross-over design. This means 
that you will be given either taurine capsule or placebo capsule for 30 
days followed by placebo capsule or taurine capsule for another 30 days. 
There will be a 2-week period of neither capsule in between. All capsules 
will be provided.  
As this is a double-blind study, neither you nor the investigators will know 
which supplement you are on at any time. At the beginning, at 30 and 60 
days of the study, you will have your usual tests (i.e weight, height, blood 
pressure etc.), blood tests to measure markers of blood vessel health and 
extra bloods for EPCs study. You will undergo a 5-minute assessment of 
how stiff your blood vessel by wearing a blood pressure cuff on your thigh 
and on your neck. You will continue taking your other medications as 
usual throughout the study. 
There is a very low risk of complications with blood test. By adhering to 
the hospital policy on blood letting, the risk of infection is very small. 
Minor bruising may be seen and this should resolve within a few days. 
Our researcher is very experience in taking blood, so the risk is very 
small. The blood pressure cuff on the thigh and neck will inflate during the 
measurement of your artery. The pressure is small and will not cause any 
discomfort to you.  
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Taurine is a naturally available protein from seafood. Similar doses of 
taurine have been used in clinical trials for up to a year without any 
adverse effect. Patients with kidney failure, seizure disorder, psoriasis 
skin disease may have the potential to develop side effect from taurine 
namely skin itching, nausea, headache and dizziness. The fact that you 
are invited to participate in the study means that we have excluded you 
from those conditions and your likelihood of having the side effects 
therefore is very low.  
Participation in this study is entirely voluntary and you may withdraw at 
any time, without giving reason, and without this decision effecting any 
future treatment or medical care. 
Our responsibilities as investigators:  
If you experience any ill effects as the result of your participation, then we 
will take care of your medical needs.  Your treatment will be unblinded so 
we can verify if these ill effects are due to the study medication.  
If we discover any medical problems such as high blood pressure or 
cholesterol, they will be discussed with you in detail, and you will be 
offered appropriate treatment and follow up in a specialist clinic or with 
your GP.   
If there are any new findings during the course of the study that may 
affect the validity of the study or your participation in it, then the findings 
will be made available to you and you will receive the appropriate medical 
care and advice depending on the test results.   
Confidentiality:  
Only anonymous data, ie. data that do not identify you by name will be 
collected. Only authorised representatives of the study team will have 
direct access to your personal medical records. All study team 
representatives and medical staffs are obliged to maintain confidentiality 
at all times.  Although we hope to publish the results at the end of the 
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study, no information that is traceable to you will be included in any such 
publication.  
For additional information now or any future time please contact:  
Dr. Wan Aizad Wan Mahmood, Research Registrar  
Connolly Hospital, Blanchardstown, Dublin 15.  Phone: 086-0229898 
 
Dr. Colin Davenport, Research Specialist Registrar (SpR) 
Beaumont Hospital, Dublin 9. Phone: 01-8092377  
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4.2.2 Consent form 
 
            
  
 
CONSENT FORM 
 
Protocol Title: The Effect of Taurine on Endothelial Dysfunction in 
Type 2 Diabetic Patients 
 
Please tick the appropriate answer. 
 
• I consent to take part in this study.     Yes  No
  
          
• I confirm that I have read and understood the Patient Information 
Leaflet attached (version 2, 18/11/2011), and that I have had ample 
opportunity to ask questions all of which have been satisfactorily 
answered.                                      
          Yes  No
  
 
• I have been given a copy of the Patient Information Leaflet and this 
Consent form for my records.       
          Yes  No 
 
• I understand that my participation in this study is entirely voluntary 
and that I may withdraw at any time, without giving reason, and 
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without this decision affecting my future treatment or medical care.
          Yes  No 
 
• I understand that my medical records may be viewed by members of 
the research team       
          Yes  No 
 
• I understand that my identity will remain confidential at all times. 
          
          Yes  No 
• I am aware of the potential risks of this study.   
          
          Yes  No 
 
• I agree that I will not restrict the use to which the results of this study 
may be put. I give my approval that anonymous data concerning my 
person may be stored or electronically processed for the purpose of 
scientific research and may be used in related or other studies in the 
future. (This would be subject to approval by an independent body 
which safeguards the welfare and rights of people in biomedical 
research studies - the Connolly Hospital and Beaumont Hospital 
Ethics (Medical Research) Committee.)    
          
          Yes  No 
 
 
Patient ___________________________      
 
_______________________________________________________ 
 Signature and dated   Name in block capitals 
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To be completed by the Principal Investigator or his nominee.  
 
I the undersigned, have taken the time to fully explain to the above 
patient the nature and purpose of this study in a manner that he/she 
could understand. I have explained the risks involved, as well as the 
possible benefits and have invited him/her to ask questions on any aspect 
of the study. 
 
   
_______________________________________________________ 
Signature, qualifications and date  Name in block capitals 
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4.2.3 Ethics Committee Approval Certificate 
 
 
--
CONNOLLY HOSPITAL BLANCHARDSTOWN
Certificate of Research Ethics Committee ADDroval
Date: 8thJune, 2012
To: Prof S Sreenan, Consultant Endocrinologist
From: DrEamon Leen, Chairman
Protocoltitle: The effect ofTaurineon EndothelialDysfunctionin Patients withType 2
Diabetes
The Research EthicsCommitteeapproved human subject involvementin your research projecton
8thJune, 2012.
There is no expirationdate for this approval, but the protocolmust be reviewedby the Ethics
Committeebefore December 31st2014. Ifthis project is to continue beyond that date, please submit
an updated proposal one month priorto the expirationdate. Ifthis proposal is used in conjunctionwith
any other human experimentationor ifit is modifiedin any way, itmust be re-approved for these
special circumstances.
Note that the followingshould be reported to the EthicsCommittee:1) all serious adverse events,
occurringat this institution,regardless ofwhether or not they are thought to be study related should be
reportedwithin2 business days to one of the members of the Research EthicsCommittee,2) any
unanticipatedproblems, and/or 3) and injuriesto subjects enrolled.
Please remember that all data includingall consent formdocuments must be returned for a minimum
of three years past the completionof the research. Additionalrequirementsmay be imposed byyour
funding source, your department, or other entities. This institution protects personal health information
of human subjects.
Dr Eamon Leen, Chairman
Approval Period: 8thJune, 2012 -31stDecember 2014
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1-E
Connolly Hospital
Blanchardstown
Dublin 15
Feidhmeannachtna SeirbhfseSliinte
Health ServiceExecutive
Tel: (01) 821 3844
Fax: (01) 646 5132
Prof S Sreenan,
ConsultantEndocrinologist,
Departmentof Endocrinology&Diabetes
ConnollyHospital
lih June, 2012.
Re: Study entitled The effect of Taurine on Endothelial
Dysfunction in Patients with Type 2 Diabetes
Dear Prof Sreenan,
Thank you for submittingamendmentsto the above studywhich has now been approved.
Warmest regards,
Yours sincerely,
~
Dr Eamon Leen,
Chairman,
Research Ethics Committee.
Connolly Hospital "Caring for all in a Tobacco Free Environment from 31st May 2009"
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4.2.4 Taurine and Placebo Documentation 
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